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The investigation of truth is in one sense difficult, in 
another easy. A sign of this is the fact that neither can 
one attain it adequately, nor do all fail, but each says 
something about the nature of things; and while each of 
us contributes nothing or little to the truth, a 
considerable amount of it results from all our 
contributions.  
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This is how it works 
You're young until you're not 
You love until you don't 
You try until you can't 
You laugh until you cry 
You cry until you laugh 
And everyone must breathe 
Until their dying breath 
 
No, this is how it works 
You peer inside yourself 
You take the things you like 
And try to love the things you took 
And then you take that love you made 
And stick it into some 
Someone else's heart 
Pumping someone else's blood 
And walking arm in arm 
You hope it don't get harmed 
But even if it does 
You'll just do it all again 
 
    “On the Radio” 
    Regina Spektor 
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When I first studied biology as an undergraduate in the early 1990’s, only a handful of genomes 
had been sequenced, and those were of viruses and organelles (Fleischmann et al. 1995). Between 
then and now, a genomic revolution has occurred (Zhang 2010). Thousands of genomes have 
been completed, including our own (Consortium 2004), and thousands more are under way 
(www.genomesonline.org). In the genomic age, rock stars have their genomes sequenced 
(www.knome.com), as do species that have never been seen or identified except by their 
distinctive genome sequences (Venter et al. 2004). In other words, genomic sequences now 
inform us of both the diversity within species (What are the genetic differences between Ozzy 
Osbourne and Craig Venter?) and the diversity of life on Earth (How many species are swimming 
in the Sargasso Sea?). Fundamental questions in molecular evolution, such as the origin of new 
genes (Ohno 1970), the molecular basis of human traits (King and Wilson 1975), and the relative 
contributions of drift and selection (Kimura 1983b) can be studied with such data on a genomic 
scale, with the goal of moving beyond the understanding of individual genes and towards an 
understanding of the patterns of gene evolution (Zhang 2010). 
In this dissertation, I examine aspects of all three of the above fundamental questions in 
molecular evolution. My first project (Chapter 2) examines the evolution of brain genes, using the 
genomic sequences of human, chimpanzee and rhesus macaque, along with several genomic gene 
expression datasets (Su et al. 2004; Semon et al. 2006), to first identify brain-specific genes and 
then compare their evolution in human and chimp, and to compare their evolution with that of
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other genes. A previous study (Dorus et al. 2004) had concluded that nervous system genes 
experienced accelerated evolution in humans, perhaps due to positive selection, but one of the 
flaws in that study was the small size of the dataset – only 24 genes were compared between 
human and chimp. Leveraging genomic sequence and expression data, I examined 686 genes 
expressed predominantly or specifically in the brain to address the question of whether a pattern 
of accelerated evolution in brain-specific genes contributed to the unique brain size and related 
cognitive capacities of humans. 
My second project (Chapter 3) also focuses on human evolution, in this case, the prevalence of 
positive selection. Again using almost 14,000 genes from the human, chimpanzee, and rhesus 
macaque genomes, I identify positively selected genes in human and chimpanzee on a genome-
wide basis. Since the neutral theory predicts that drift plays a more important role in species with 
a small effective population size(Kimura 1983a), like human, compared to those with a larger 
effective population size, like chimpanzee (Chen and Li 2001), it is interesting to compare the 
action of drift and positive selection in the two species. Despite the anthropocentric view that 
humans have many more beneficial traits than chimps, in fact, I found that chimpanzees have 
more genes that have experienced positive selection than humans have. This finding and other 
aspects of the human and chimpanzee genomes are consistent with reduced efficacy of selection 
in humans compared to chimps. 
My final project focuses on the processes that lead to new genes by examining patterns of 
evolution in 12 Drosophila genomes and using those patterns to simulate long-term evolution of 
genes (Chapter 4). After evolution under gradual and punctuated models (Domazet-Loso and 
Tautz 2003), I assess the extent to which genes retain sequence similarity with their homologs. 
Findings from this study indicate that it is difficult to distinguish between new and old genes, due 
to both classifying old genes as new, and classifying new genes as old. In addition, this work 
shows that the combination of gene duplication with both gradual and punctuated evolution are 
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not sufficient to account for the observed number of young genes in Drosophila, indicating that 
other mechanisms, such as gene origination from non-coding regions, must also be at work.  
Each of these studies examines the majority of genes in multiple genomes to obtain information 
about how genes in general evolve. Another common theme that unites these studies is the 
importance of careful design in genomic studies. For example, in the study about brain genes, we 
found that simply defining a “brain gene” is no trivial task. We used several different definitions 
to try to capture a core set of brain genes, taking into account level and specificity of expression 
as well as functional annotations where available. In the study about positive selection in human 
and chimp, great care was taken to ensure that the lower quality of the chimp genome compared 
to the human genome did not influence the results. A naïve comparison of positive selection in 
human and chimp, without taking this bias into account, could only yield spurious results. 
Finally, in my third study about evolutionary patterns of new genes in Drosophila, I confront the 
issue of bias directly by comparing published results about genes of different ages with simulated 
results that incorporate biased measurement, and I find that at least some published results 
attributed to biological processes(Domazet-Loso et al. 2007) can be more parsimoniously 
explained by biased measurement of gene age. Taken together, these studies shed light on the 
patterns of molecular evolution, and also remind us that great care must be taken to ensure that 





Did brain-specific genes evolve faster in humans than in chimpanzees? 
Abstract 
One of the most distinctive characteristics of humans among primates is the size, organization 
and function of the brain. A recent study has proposed that there was widespread accelerated 
sequence evolution of genes functioning in the nervous system during human origins. Here we 
test this hypothesis by a genome-wide analysis of genes that are expressed predominantly or 
specifically in brain tissues and genes that have important roles in the brain, identified on the 
basis of five different definitions of brain specificity. Although there is little overlap among the 
five sets of brain-specific genes, none of them supports human acceleration. On the contrary, 
some datasets show significantly fewer nonsynonymous substitutions in humans than in 
chimpanzees for brain-specific genes relative to other genes in the genome. Our results suggest 
that the unique features of the human brain did not arise by a large number of adaptive amino acid 
changes in many proteins.  
Introduction 
The human brain differs substantially from those of other primates in size, organization and 
function. For instance, in comparison to that of chimpanzees, the brain weight of humans is over 
300% greater but the body is only 35% heavier (Williams 2002) (Figure 2.1). The structural 
asymmetry between the left and right hemispheres is especially pronounced in human brains 
(Deacon 1994). Humans also have speech or language and other high-order cognitive functions 
that are absent in non-human primates. The genetic changes that have been responsible for the 
emergence of these human-unique brain features are a topic of enduring interest. Generally 
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speaking, the marked evolution of the human brain could be due to modifications of either a small 
or a large number of genes, where the modifications might be in gene expression or protein 
function. 
If widespread changes in many genes were the cause of human brain evolution, the signatures of 
such events might be identifiable from a genome-wide analysis. Recently, Dorus et al. (Dorus et 
al. 2004) analyzed a set of nervous system genes at the protein sequence level and found that 
these genes evolved significantly faster in primates than in rodents, in hominoids than in Old 
World monkeys, and in humans than in chimpanzees. They further suggested that the accelerated 
evolution was due to positive Darwinian selection for advantageous amino acid changes. Their 
analysis, however, suffered from four shortcomings. First, they compared only 24 nervous system 
genes between human and chimpanzee – the most relevant species pair for studying evolution of 
the human brain. Second, their list of nervous system genes was manually compiled and might 
thus be incomplete or biased (see later). Third, they used house-keeping genes as controls in some 
of the analyses, which seems inappropriate because tissue-specific genes and house-keeping 
genes are expected to have different evolutionary patterns (Duret and Mouchiroud 2000; Zhang 
and Li 2004). Fourth, a recent comparison between the dog and mouse genomes found that 18 
nervous system genes that evolved faster in primates than in rodents also evolved faster in 
carnivores than in rodents (Lindblad-Toh et al. 2005), suggesting that the findings of Dorus et al. 
(Dorus et al. 2004) might partially be due to rodent deceleration rather than primate acceleration. 
A more recent analysis of 5,268 genes has also found more amino acid substitutions in humans 
than in chimpanzees for brain-specific genes; however, the statistical significance of the 
difference is uncertain (P = 0.03–0.08, depending on which genes are used as controls) and the 
results are inconclusive (Khaitovich et al. 2005). 
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Here we conduct a comparison of sequence evolution of brain-specific genes between the human 
and chimpanzee lineages, using genome sequences of human, chimpanzee and macaque monkey, 
and human transcriptome data. 
Compilation of the primate gene dataset 
From Ensembl (http://www.ensembl.org), we obtained the DNA and amino acid sequences of all 
of the proteins predicted from the genome sequences of human (Homo sapiens), chimpanzee (Pan 
troglodytes) and macaque (Macaca mulatta). To identify orthologous genes, we used human 
proteins as queries to search chimpanzee proteins with BLASTP (see Supplementary Methods). 
Reciprocal best hits are considered as orthologs. Similarly, we used human sequences to search 
the macaque proteins with BLASTP. A total of 19,422 proteins with reciprocal best hits in both 
the human–chimpanzee and the human– macaque searches were found, and alignments of the 
human–chimpanzee–macaque orthologous proteins were obtained. 
We discarded alignments containing fewer than 100 amino acids because most of these were 
caused by gaps in draft genome sequences. DNA sequence alignments were obtained from the 
protein alignments. We further removed 161 alignments that showed exceptionally high 
divergences among the species and were probably the results of misalignment or non-orthology 
(see Supplementary Methods). The proportion of brain-specific genes was lower in the removed 
alignments than in the remaining alignments. Finally, each protein was assigned to a gene on the 
basis of its Ensembl annotation, resulting in 13,955 distinct genes for further analysis. After the 
removal of alignment gaps, these genes contain 18,287,982 nucleotide sites or 6,095,994 codons, 
covering >50% of all protein coding regions in a primate genome. 
We consider that a nucleotide position has a human-specific substitution if the sequence is 
identical between the chimpanzee and macaque but different in human at this position. We 
similarly define chimpanzee specific substitutions. A nucleotide substitution is then classified as 
either synonymous or nonsynonymous depending on whether it alters the amino acid encoded. 
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We observed 57,545 chimpanzee-specific nucleotide substitutions and 50,254 human-specific 
substitutions. Thus, the nucleotide substitution rate seems to be 1.15 times (57,545/50,254) higher 
in chimpanzees than in humans. This rate difference is probably due to the relatively low quality 
of the 4-coverage chimpanzee draft genome sequence (Consortium 2005), as compared with that 
of the finished human genome sequence (Consortium 2004). 
A recent study estimated that the error rate in the chimpanzee genome sequence has an upper 
limit of 0.07% (Taudien et al. 2006), ~70 times higher than the error rate in the human sequence 
(Consortium 2004). The observed chimpanzee to human divergence is 0.59% in our dataset of 
coding sequences. If we assume that the actual substitution rates in humans and chimpanzees are 
identical, then the chimpanzee to human substitution rate ratio (RC/H) might appear as high as 
1.27, simply because of the 0.07% sequencing errors in the chimpanzee genome (Supplementary 
Methods). If we also consider that the mutation rate per year is slightly (3%) lower in humans 
than in chimpanzees (Elango et al. 2006), RC/H might appear as high as 1.30 (Supplementary 
Methods). Our RC/H value of 1.15 is within these limits. Our result is also comparable to a recent 
estimate of 1.11–1.18 for the RC/H for large numbers of intergenic sequences and introns obtained 
from a comparison of the draft chimpanzee genome sequence and the finished human sequence 
(Elango et al. 2006). 
Several measures of the rate of protein sequence evolution have been well established by 
molecular evolutionists (Nei and Kumar 2000). For example, let n be the number of 
nonsynonymous substitutions for a group of genes in a particular lineage and s be the 
corresponding number of synonymous substitutions; and let N and S be the numbers of 
nonsynonymous and synonymous sites, respectively, for the group of genes (Nei and Kumar 
2000). For any large group of genes in our dataset, N/S = 2.45 (Supplementary Methods). Thus, 
the nonsynonymous- to-synonymous rate ratio (ω), which is commonly used to measure the rate 
of protein evolution controlled by the mutation rate, becomes (n/N)/(s/S) = (n/s)/(N/S) = (n/s)/ 
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2.45 = 0.408n/s. Because most genes in a genome have a ω value of <1, whereas sequencing 
errors are expected to have a ω value of 1, the errors cause overestimation of ω. Thus, we would 
see a higher ω for chimpanzees than for humans owing to chimpanzee sequencing errors. 
Furthermore, the bias is more serious for genes with low ω than for genes with high ω (when 
ω<1). Because brain-specific genes tend to have lower ω values than other genes in the genome 
(Table 2.1), the former are affected by sequencing errors to a greater extent than the latter. Thus, 
we expect to observe a higher ω in chimpanzees than in humans for brain-specific genes, even 
when benchmarked by other genes in the genome (Table 2.2). 
To rectify this problem, we add the same number of random ‘sequencing errors’ to the human 
genome sequence as the number that occurred in the chimpanzee sequence. Although sequencing 
errors will still affect the ω of brain specific genes more than that of other genes, the human and 
chimpanzee lineages can now be compared. Assuming that the total numbers of substitutions in 
our 13,955 genes are equal between the human and chimpanzee lineages, we estimate that the 
error rate in the chimpanzee sequence is 0.04%, which is equal to 7,315 errors (Supplementary 
Methods). We thus randomly add this number of errors to the human sequence and then compare 
the human and chimpanzee sequences. Although the 4.6-coverage macaque genome sequence 
might also contain numerous sequencing errors, these errors are not expected to bias our 
comparison between human and chimpanzee because the macaque is used as an outgroup. 
Analysis of brain-specific genes 
It is not an easy task to define those genes that function specifically in the brain. We therefore use 
five different definitions to examine whether they provide consistent results. 
Analysis based on microarray data 
Our first definition is based on a human microarray gene expression dataset (Su et al. 2004), 
which includes the expression signals of almost all human genes in 73 normal tissues. Because 
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many of the 73 tissues are from the same organs, we group the tissues into 40 tissue groups 
(Table 2.3). For example, the brain tissue group includes 17 tissues that represent different 
developmental stages or parts of the brain. Brain-specific genes are defined as those genes for 
which the highest expression is found in one of the brain tissues and this highest expression is at 
least twice the expression level in any non-brain tissues. As a result, 249 brain-specific genes are 
identified. Similarly, we identified tissue-specific genes for the other 39 tissue groups, and the 
total number of these other tissue-specific genes is 1,544. The remaining 12,162 genes are 
referred to as non-tissue-specific genes. For our second definition, we used the same human 
microarray gene expression dataset but with more stringent criteria, requiring that the highest 
expression level in a brain tissue is at least four times that in any non-brain tissue for a gene to be 
called brain-specific. Because the results based on these two definitions are almost identical, 
below we describe in detail only those from the first definition (Table 2.1, ‘Microarray [2X]’; see 
‘Microarray [4X]’ for the results from the second definition). 
We find that, for brain-specific genes, the ω value in the human lineage (ωH) is 0.205 and that in 
the chimpanzee lineage (ωC) is 0.198. Their ratio (ωH=ωC ¼ 1:03) is not significantly different 
from 1 (P > 0.5, x2-test; Table 2.1). As a comparison, ωH=ωC equals 1.06 (P > 0.05) for other 
tissue-specific genes, 1.12 (P < 10
-4
) for non-tissue-specific genes, and 1.11 (P < 10
-4
) for all of 
the genes considered together. The observation of ωH=ωC >1 for all genes together is consistent 
with previous findings and is explainable by a smaller effective population size and thus weaker 
purifying selection and a higher nonsynonymous substitution rate in the human lineage than in the 
chimpanzee lineage (Eyre-Walker and Keightley 1999; Consortium 2005; Khaitovich et al. 
2005). We find that the ωH=ωC ratio of brain-specific genes is slightly lower than that of other 




Similar results are obtained when brain-specific genes are compared with non-tissue-specific 
genes (Table 2.1). Because the same genes are compared between human and chimpanzee, we 
can compute the ratio of the number of nonsynonymous substitutions in the human lineage (nH) to 
that in the chimpanzee lineage (nC) and compare this ratio (nH/nC) between different groups of 
genes. Interestingly, we find that nH/nC is significantly lower for brain-specific genes than for 
non-tissue-specific genes (P = 0.04, χ
2
-test; Table 2.1), suggesting a possible human slowdown 
(or chimpanzee acceleration) of the evolution of brain-specific genes, when benchmarked by non-
tissue-specific genes.  
The nH/nC values are not, however, significantly different between brain-specific genes and other 
tissue-specific genes, or between other tissue-specific genes and nontissue- specific genes. 
Analysis based on EST data 
Because the microarray data might be inaccurate (Liao and Zhang 2006), we repeated the above 
analysis using a third definition of brain-specific genes based on expression sequence tags 
(ESTs). Here, tissue-specific genes are those for which ESTs are found in only one tissue. We 
used a recently compiled human EST dataset that includes 4.9 million ESTs from 44 tissues 
(Semon et al. 2006) and classified the 13,955 primate genes into 165 brain-specific genes (i.e. 
ESTs are found only in the brain), 819 other tissue-specific genes, and 12,971 non-tissue-specific 
genes. The results from the EST data (Table 2.1) are similar to those from the microarray data. 
Although ωH=ωC is significantly greater than 1 for other tissue-specific genes and non-tissue-
specific genes, it is not significantly greater than 1 for brain-specific genes. Consequently, the 
ωH=ωC ratio is slightly lower for brainspecific genes than for other genes, although the difference 
is not statistically significant (Table 2.1). Similarly, the nH/ nC ratio appears lower, although not 
significantly, in brainspecific genes than in other genes (Table 2.1). 
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Analysis based on SAGE data 
We also repeated the above analysis using a fourth definition of tissue specificity based on serial 
analysis of gene expression (SAGE). Brain-specific genes are defined as those for which SAGE 
tags are detected only in the brain. On the basis of a recently compiled SAGE dataset (Semon et 
al. 2006) the 13,955 primate genes include 209 brain-specific genes and 632 other tissue-specific 
genes. The remaining genes are considered to be non-tissue-specific. The results obtained from 
the SAGE data (Table 2.1) are similar to those from the microarray and EST data. That is, there is 
no significant difference between ωH and ωC for brain-specific genes, regardless of whether other 
genes are used as controls or not. There is also no significant difference between the nH/nC ratios 
of brain-specific genes and other genes. 
Analysis based on a list of nervous system genes Dorus et al. (Dorus et al. 2004) compiled a list 
of 214 nervous system genes on the basis of (i) literature suggesting important gene functions in 
the nervous system, (ii) SAGE and EST data showing gene expression exclusively or 
predominantly in the brain, and (iii) information on genes implicated in nervous system diseases 
(Dorus et al. 2004). We found 146 of these 214 genes in our list of 13,955 primate genes. Because 
Dorus et al. (Dorus et al. 2004) did not define other tissue-specific genes, we analyzed these 
nervous system genes by using the remaining 13,809 genes in our dataset as a control. We find no 
significant difference between ωH and ωC for nervous system genes, with or without comparison 
to other genes (Table 2.1). Dorus et al. (Dorus et al. 2004) suggested that the human lineage 
acceleration is particularly pronounced for a subset of genes that control nervous system 
development, but is absent for genes with physiological roles and minimal for the remaining (i.e. 
unclassified) nervous system genes. Our data, however, provide no statistical evidence for these 
claims (Table 2.1). We also failed to detect a difference in nH/ nC between nervous system genes 
(or developmental nervous system genes) and other genes (Table 2.1). 
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The main reason why we cannot repeat the result of the faster evolution of humans than 
chimpanzees even when we use the list of nervous system genes that Dorus et al. (Dorus et al. 
2004) compiled seems to be because Dorus et al. did not compare all of the 214 nervous system 
genes between human and chimpanzee. Instead, between humans and chimpanzees they 
compared only 24 genes that were known to evolve faster in the human lineage than in the 
macaque lineage when the squirrel monkey was used as an outgroup. In other words, they used a 
small and biased gene set in their human–chimpanzee comparison. 
Caveats 
Although our results from the five analyses are congruent in showing that there has been no 
accelerated evolution of human brain-specific genes, this congruence would be expected if there 
were large overlaps among the five groups of brain-specific genes identified under the five 
different definitions. Interestingly, however, except for those identified by the two microarray-
based definitions, only a few genes overlap from any two of the five groups of brainspecific 
genes and no genes overlap among all five groups (Figure 2.2). 
Although this finding suggests that the five analyses are largely independent, it also raises the 
issue of how to identify brain-specific genes accurately. The level of gene expression in a tissue is 
a continuous variable. For the EST (or SAGE) data, we identified brain-specific genes as those 
that lack ESTs (or SAGE tags) in non-brain tissues, which actually means genes that have a lower 
expression level in non-brain tissues than in the brain. This definition is qualitatively the same as 
that used for the microarray data, where brain-specific genes are required to show expression at 
least twice as high in the brain as in any other tissue. Although it might be argued that a gene that 
exclusively functions in the brain could have a lower expression in this organ than in other 
tissues, such a situation is unlikely, particularly when expression in the brain is defined by the 
highest expression level among all temporal and spatial brain samples. 
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All five definitions that we used consider gene expression patterns, although the fifth definition 
also includes genes with known brain functions and genes implicated in brain diseases. On the 
one hand, considering gene function provides additional information that might help to reduce the 
reliance on gene expression, which is sometimes a poor indicator of function. On the other hand, 
gene function information is usually incomplete and it is difficult to know whether a gene 
functions exclusively in the brain. Our results suggest that it is still a challenging task to define 
genes that function specifically in a tissue. A potential way of increasing the accuracy of 
identifying brain-specific genes is to use more than one criterion. We therefore analyzed a subset 
of 74 genes that are brain-specific by at least two of our definitions 1, 3, 4, and 5; we excluded 
definition 2 because it is a subset of definition 1 (Figure 2.2). The difference between ωH and ωC 
of brain-specific genes, with or without comparison to other genes in the genome, is still not 
significant (Table 2.1). Interestingly, however, the nH/nC ratio is significantly lower for brain-
specific genes than for other genes in the genome (Table 2.1). 
Our analysis also highlights the intricacy of genomewide comparisons between humans and 
chimpanzees in the presence of sequencing errors. As eloquently articulated by Taudien et al. 
(Taudien et al. 2006), a small leak can sink a great ship. In our analysis, the chimpanzee 
sequencing errors, when not appropriately controlled, generate a significantly higher ωC than ωH 
for brain-specific genes, even when compared with other genes in the genome (Supplementary 
Table 2.1). This difference disappears when we add the same number of ‘sequencing errors’ to 
the human sequence. In our addition of sequencing errors to the human sequence, we assumed 
that the substitution rate for the whole set of 13,955 genes is identical between the human and 
chimpanzee lineages. If the mutation rate is slightly lower in humans than in chimpanzees 
(Elango et al. 2006) and the total substitution rate is also lower in humans than in chimpanzees, 
we might have added more ‘sequencing errors’ than needed, which would have raised ωH=ωC and 
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favored the human acceleration hypothesis. In other words, our result of no human acceleration is 
conservative (see also Supplementary Methods). 
To verify the results obtained from our approach of error addition, we also used the approach of 
error removal. We removed errors from the chimpanzee sequence by using only nucleotide sites 
with quality scores Q20 (or accuracy > 99%) (Consortium 2005). The new dataset contained 
13,888 genes. Again, none of the analyses shows a significantly higher evolutionary rate of brain-
specific genes in humans than in chimpanzees (Table 2.4). 
Concluding remarks 
We have analyzed almost 14,000 human, chimpanzee and macaque genes to test the hypothesis 
that human brainspecific genes have undergone widespread accelerated protein-sequence 
evolution since the human lineage separated from the chimpanzee lineage. Our results, based on 
five different definitions of brain-specificity, show no evidence that supports this hypothesis. 
Because our data include over 50% of all human genes, it is appropriate to conclude that our 
results reject the hypothesis of widespread accelerated sequence evolution of human brainspecific 
genes. 
In fact, in several but not all of our analyses, the nH/nC ratio is significantly lower for brain-
specific genes than for other genes in the genome, suggesting that – relative to other genes – 
brain-specific genes evolved more slowly in humans than in chimpanzees. This phenomenon 
might reflect higher importance of brain-specific genes and therefore stronger purifying selection 
on them in human evolution than in chimpanzee evolution. Our findings imply that the unique 
features of the human brain did not arise by a large number of adaptive amino acid substitutions 
in many proteins. This conclusion, however, does not preclude the possibility that substantial 
accelerations occurred in the evolution of a few nervous system genes during human origins. 
Indeed, several such examples are known, including genes that control brain size and speech 
development (Enard et al. 2002b; Zhang et al. 2002; Zhang 2003; Evans et al. 2004a; Evans et al. 
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2004b; Kouprina et al. 2004; Wang and Su 2004). It also remains possible that the origin of the 
human-unique brain features was due to expression changes (rather than coding sequence 
changes) of many genes, as has been suggested from some microarray data (Enard et al. 2002a; 
Khaitovich et al. 2005) (but see also Refs (Hsieh et al. 2003; Uddin et al. 2004; Lemos et al. 
2005)). 
Supplementary methods 
Primate gene dataset 
Protein and corresponding DNA sequences of all predicted genes in the human, chimpanzee, and 
macaque genome sequences were downloaded from Ensembl v 35 (November 2005, 
http://www.ensembl.org). To identify orthologous genes, human protein sequences (n= 33,869) 
were used to conduct BLASTP searches (Altschul et al. 1990) against the chimpanzee (n = 
39,648) and macaque (n = 31,371) protein sequences. Reciprocal searches were performed using 
the chimpanzee and macaque proteins to query the human proteins. 19,422 proteins with 
reciprocal best hits in both human/chimpanzee and human/macaque searches were retained for 
further analysis. 
Alignment of the human-chimpanzee-macaque orthologous proteins was performed using 
CLUSTALW v 1.83 (Thompson et al. 1994). DNA sequence alignments were obtained following 
the protein sequence alignments. Alignments containing fewer than 100 amino acids ( n= 1,291) 
were discarded. Lineage-specific nucleotide substitutions were identified as described in the main 
text. Review of several alignments with exceptionally high proportions of human- or chimpanzee-
specific changes revealed that they resulted from incorrect alignment or non-orthology. 
Therefore, alignments containing greater than 10% human or chimpanzee-specific amino acid or 
nucleotide changes or greater than 30% macaque-specific changes were discarded from analysis 
(n = 161). Finally, each protein was assigned to a gene based on the Ensembl annotation, and the 
protein sequence with the longest amino acid alignment was retained for each gene, resulting in 
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the alignments of human, chimpanzee, and macaque sequences of 13,955 distinct genes. Using 
modified Nei-Gojobori method (Zhang et al. 1998) with a transition/transversion ratio of 2 
(Rosenberg et al. 2003), we estimated that the total number of nonsynonymous sites in these 
13,955 genes was N = 12,986,068 and the total number of synonymous sites was S = 5,301,914, 
with their ratio being N/S = 2.45. We used the parsimony approach to identify human-specific 
and chimpanzee-specific substitutions (see main text). This approach is justified because of the 
low divergence of the sequences concerned in this paper. The observed human-chimpanzee 
divergence is 0.59% in our dataset of coding sequences. A recent study estimated that the error 
rate in the chimpanzee genome sequence has an upper limit of 0.07% (Taudien et al. 2006). 
Assuming this error rate, the actual divergence between the two species is 0.59% − 0.07% = 
0.52%. If we assume that the actual substitution rates in humans and chimpanzees are identical, 
the proportion of sites with chimpanzee substitutions (including sequencing errors) is 0.52% ÷ 2 
+ 0.07% = 0.33%, whereas the proportion of sites with human substitutions is 0.59% − 0.33% = 
0.26%. The chimpanzee/human substitution rate ratio (RC/H) becomes 0.33 ÷ 0.26 = 1.27. If we 
consider that the substitution rate is 2 3% lower in humans than in chimpanzees (Elango et al. 
2006), the proportion of sites with chimpanzee substitutions is 0.52% ÷ 1.97 + 0.07% = 0.334%, 
whereas the proportion of sites with human substitutions is 0.59% − 0.334% = 0.256%. Their 
ratio RC/H is 0.334% ÷ 0.256% = 1.30. 
We estimated the rate of sequencing error in the chimpanzee sequence as follows. We assume 
that the substitution rates are equal between humans and chimpanzees. Thus,RC/H 
.%  	
/  	 
.%  	
/ , 
where x is the error rate. Given the observed RC/H of 1.15, we estimated that x = 0.04%. Under the 
assumption of a 3% reduction of substitution rate in humans than in chimpanzees, the sequencing 
error rate is estimated to be 0.033%. The above RC/H was estimated using all substitutions. If only 
synonymous substitutions are used, RC/H = 1.10. Thus, the error rate may be lower than the above 




The microarray gene expression data for 73 human normal tissues and the nucleotide sequences 
for 27,215 probesets were obtained from ref. (Su et al. 2004). The probeset sequences were used 
to perform BLAST searches against the human coding sequences from Ensembl. Probesets that 
matched to multiple genes were considered ambiguous and discarded. 26,195 probesets were 
unambiguously matched to 16,605 distinct genes. Of these genes, 12,145 had human-
chimpanzee-macaque alignments. For genes that matched to more than one probeset, the 
expression levels measured in each probeset were averaged for each tissue replicate. Two 
replicates were available for each tissue; these were averaged to determine the expression level of 
a gene in a tissue. Multiple tissues representing same organs were consolidated into tissue groups 
(Table 2.3). For any given gene, a single representative expression level was used for a tissue 
group by taking the highest expression level from the group. 
The microarray expression data was analyzed in two ways. First, we identified 2,432 genes for 
which the expression level in the highest tissue group was equal to or greater than two times the 
expression level in the second highest tissue group. These genes are said to be tissue-specific in 
the highest tissue. All other genes in our primate gene dataset were treated as non-tissue-specific 
genes. Second, we used a more stringent criterion of tissue-specificity, requiring that the 
expression level in the highest tissue group be at least four times the expression level in the 
second highest tissue group. 
EST and SAGE data 
The human expression sequence tag (EST) and serial analysis of gene expression (SAGE) data 
were compiled by Semon et al. (Semon et al. 2006) and kindly supplied by the authors. Semon et 
al. (Semon et al. 2006) selected from GenBank 4.9 million ESTs from human tissues. cDNA 
libraries from cell culture, tumors, pooled organs, or unidentified tissues were excluded, and 
cDNA libraries that had been sufficiently sampled (>10,000 ESTs) were retained, resulting in 44 
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tissues corresponding to 141 libraries. These authors further removed those tissues with fewer 
than 30 tissue-specific genes, resulting in the final dataset of 2,126 tissue-specific genes from 18 
tissues. The SAGE data contained 1,190 tissue-specific genes from 12 tissues. In both of these 
datasets, a gene was considered to be tissue-specific if its transcript was detected in only one 
tissue. All other genes were treated as non-tissue-specific. 
Dorus et al.’s (2004) data 
We also acquired the list of nervous system genes from Dorus et al. (Dorus et al. 2004). Of 214 
genes in this dataset identified by gene symbol, we were able to find 146 that are present in our 
primate gene dataset. 
Simulation tests 
As described in the main text, we defined ωH and ωC by 0.408n/s for a group of genes in the 
human and chimpanzee lineages, respectively. We used the χ
2
 test with 1 degree of freedom to 
compare ωH and ωC. We compared ωH/ωC values between two groups of genes by computer 
simulation. For example, we compute the ratio (r) of the ωH/ωC value from brain-specific genes 
to that of other tissue-specific genes and then examine the sampling variance of r by simulation. It 
is obvious that n and s are both Poisson random variables when the rate of substitution is given. 
For a given n (or s), we generate 10,000 Poisson random numbers with the mean equal to the 
observed n (or s). Thus, we can obtain 10,000 random r values, which represent the variation of r. 
A two-tail test is then conducted. That is, we consider our observed r to be significantly different 
from 1 at the 5% level when fewer than 250 randomly generated r values are greater than 1 or 
smaller than 1. Use of one-tail tests does not change any of our conclusions in the paper. The Q20 
dataset We also compiled a dataset by using those nucleotide sites in the chimpanzee genome 
sequence with quality scores ≥20 (Q20, or accuracy >0.99). Chimpanzee codons retained for 
analysis must have quality scores ≥20 at all codon positions. The quality score information was 
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downloaded from http://www.genome.ucsc.edu. The data were further cleaned using the same 
criteria as described in the first section. The final dataset contained 13,888 genes. 
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Figure 2.1 Evolutionary tree of human, chimpanzee and macaque monkey. 
Also shown are the brains of the three species drawn to scale and the encephalization quotients 
(EQs). The EQ measures the brain mass relative to the total body mass and is computed by E/Pa, 
where E is the brain mass, P is the body mass, and a is the exponent. The EQ values are taken 
from (Williams 2002); a = 0.75 on the basis of previous analyses of primates (Martin 1981) or 
catarrhine primates (i.e. humans, apes and Old World monkeys) (Pagel and Harvey 1989). The 





Figure 2.2 Venn diagram of brain
definitions. 
The number of genes is given in each circle. The overlapping sets of the nervous system genes 
(from Dorus et al. (Dorus et al. 2004




-specific genes identified on the basis of five different 






Table 2.1 Evolutionary rates of brain-specific genes and other genes in humans and chimpanzees 
 
a Number of nonsynonymous substitutions in the lineage indicated. 
b Number of synonymous substitutions in the lineage indicated. 
c Nonsynonymous/synonymous substitution rate ratio, computed by 0.408n/s. 
d Statistically significant deviation from 1 is indicated by asterisks: Significance level: *P < 0.05, **P < 0.01, ***P < 
0.001, ****P < 0.0001. Simulation tests are used for comparing ratios between groups of genes, whereas χ2-tests are 
used within groups of genes. 
e Statistically significant deviation from 1 (between groups of genes) is indicated by asterisks. χ2-tests are used. 
f From Dorus et al. (Dorus et al. 2004). 
g Genes identified to be brain-specific in at least two of the four definitions (‘Microarray [2X]’, ‘EST’, ‘SAGE’ and 




Table 2.2 Comparison of the evolutionary rates of brain-specific genes and other genes in human 
and chimpanzee lineages using microarray 2X definition of tissue-specificity and unmodified 
genome sequences. 
 
1 Number of nonsynonymous substitutions in the lineage indicated. 
2 Number of synonymous substitutions in the lineage indicated. 
3 Nonsynonymous/synonymous substitution rate ratio, computed by 0.408n /s . 
4 Statistically significant deviation from 1 is indicated by asterisks. Significance level: *, 5%; **, 1%; ***, 0.1%; ****, 
0.01 





Table 2.3 Tissue groups considered in the analysis of the microarray data 
Tissue Group Tissues Combined 
721B lymphoblasts 721B lymphoblasts 
Adipocyte Adipocyte 
Adrenal cortex Adrenal cortex 
Adrenal gland Adrenal gland 
Appendix Appendix 
Atrioventricular node Atrioventricular node 
BM BMCD33 myeloid, BMCD105 endothelial, BMCD34, BMCD71 early 
erythroid 
Bone marrow Bone marrow 
Brain temporal lobe, globus pallidus, cerebellum peduncles, cerebellum, caudate 
nucleus, whole brain, parietal lobe, medulla oblongata, amygdala, prefrontal 
cortex, occipital lobe, hypothalamus, thalamus, subthalamic nucleus, 
cingulated cortex, pons, fetal brain 
Bronchial epithelial cells Bronchial epithelial cells 
Cardiac myocytes Cardiac myocytes 




Liver liver, fetal liver 
Lung lung, fetal lung 
Lymph node Lymph node 
Olfactory bulb Olfactory bulb 
Ovary Ovary 
Pancreas pancreas, pancreatic islets 
Pathogenic (excluded) colorectal adenocarcinoma, leukemia lymphoBLASTic molt 4, lymphoma 
burkitts Raji, leukemia promyelocytic hl60, lymphoma burkitts Daudi, 
leukemia chronicmyelogenous k562 
PB PBCD14 monocytes, PBBDCA4 dentritic cells, PBCD56NK cells, PBCD4T 




Salivary gland Salivary gland 
Skeletal muscle Skeletal muscle 
Skin Skin 
Smooth muscle Smooth muscle 
Spinal cord Spinal cord 
Superior cervical ganglion Superior cervical ganglion 
Testis testis, leydig cell, germ cell, testis interstitial, seminiferous tubule 
Thymus Thymus 




Trigeminal Ganglion Trigeminal Ganglion 
Uterus Uterus 
Uterus Corpus Uterus Corpus 





Table 2.4 Comparisons between evolutionary rates of brain-specific genes and other genes in 
human and chimpanzee lineages using high quality (Q20) chimpanzee sequences. 
 
1
 Number of nonsynonymous substitutions in the lineage indicated. 
2
 Number of synonymous substitutions in the lineage indicated. 
3
 Nonsynonymous/synonymous substitution rate ratio, computed by 0.408n /s . 
4 
Statistically significant deviation from 1 is indicated by asterisks. Significance level: *, 5%; **, 1%; ***, 
0.1%; ****, 0.01%. Simulation tests are used for comparing ratios between groups of genes, whereas χ2 
tests are used within groups of genes. 
5
 Statistically significant deviation from 1 (between groups of genes) is indicated by asterisks. χ2 tests are 
used. 
6
 Genes identified to be brain-specific in at least two of the four definitions (microarray 2X, EST, SAGE, 




More genes underwent positive selection in chimpanzee evolution than 
in human evolution 
Abstract 
Observations of numerous dramatic and presumably adaptive phenotypic modifications during 
human evolution prompt the common belief that more genes have undergone positive Darwinian 
selection in the human lineage than in the chimpanzee lineage since their evolutionary divergence 
6–7 million years ago. Here, we test this hypothesis by analyzing nearly 14,000 genes of humans 
and chimps. To ensure an accurate and unbiased comparison, we select a proper outgroup, avoid 
sequencing errors, and verify statistical methods. Our results show that the number of positively 
selected genes is substantially smaller in humans than in chimps, despite a generally higher 
nonsynonymous substitution rate in humans. These observations are explainable by the reduced 
efficacy of natural selection in humans because of their smaller long-term effective population 
size but refute the anthropocentric view that a grand enhancement in Darwinian selection 
underlies human origins. Although human and chimp positively selected genes have different 
molecular functions and participate in different biological processes, the differences do not 
ostensibly correspond to the widely assumed adaptations of these species, suggesting how little is 
currently known about which traits have been under positive selection. Our analysis of the 
identified positively selected genes lends support to the association between human Mendelian 
diseases and past adaptations but provides no evidence for either the chromosomal speciation 




Although humans and their closest living relatives, chimpanzees, are highly similar at the 
genomic level (Chen and Li 2001; Britten 2002; Ebersberger et al. 2002; Wildman et al. 2003; 
Watanabe et al. 2004; Consortium 2005), they differ in many morphological, physiological, and 
behavioral traits (Varki and Altheide 2005). Phenotypically, modern humans appear to have 
changed considerably more than modern chimps from their common ancestors (King and Wilson 
1975; Pilbeam 1996; Olson and Varki 2003; Varki and Altheide 2005). Many of these 
evolutionary modifications in humans, such as the origins of bipedalism, speech and language, 
and other high-order cognitive functions, are widely thought to be adaptive (Darwin 1871; 
Vallender and Lahn 2004; Sabeti et al. 2006). These observations led to a common belief that 
more genes underwent positive Darwinian selection in the human lineage than in the chimpanzee 
lineage. Indeed, there are more reports of positively selected genes (PSGs) in humans than in 
chimps (Vallender and Lahn 2004; Sabeti et al. 2006). Nonetheless, this difference may be 
largely due to a lack of study in chimps. To avoid such a bias, one could identify and compare all 
PSGs from the human and chimp genomes. Positive selection acting on a protein-coding gene 
may be detected by various population genetic and molecular evolutionary methods that use 
intraspecific polymorphism data, interspecific divergence data, or a combination of the two (Li 
1997; Nei and Kumar 2000; Nielsen 2005). However, because of the paucity of polymorphism 
data from chimps, a fair comparison between the two species would have to be limited to the 
divergence data. Such data can be used to estimate the ratio of nonsynonymous to synonymous 
substitution rates (ω). An ω value significantly >1 indicates the action of positive selection, 
whereas an ω significantly <1 indicates negative (or purifying) selection. Using this approach, 
two earlier studies (Clark et al. 2003; Arbiza et al. 2006) pioneered the identification of human 
and chimp PSGs at the genomic scale, although no comparison was made between the numbers of 
human and chimp PSGs. In fact, the studies’ results would be unsuitable for the comparison, 
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owing to a number of deficiencies. First, both studies used the mouse as an outgroup, to 
distinguish between human-specific and chimp-specific nucleotide substitutions, because of the 
unavailability of genome sequences from any closer outgroups at that time. Because mouse is 
distantly related to human and chimp, this practice introduces errors. Second, one of the studies 
(Clark et al. 2003) was based on less reliable statistical methods and assumptions (Zhang 2004), 
whereas the other (Arbiza et al. 2006) used the draft chimp genome sequence (Consortium 2005) 
known to contain many more errors than the finished human genome sequence (Shi et al. 2006; 
Taudien et al. 2006). Because the majority of genes in a genome have ω < 1, and sequencing 
errors have an expected ω of 1, the errors inflate ω and the false detection of positive selection. In 
this work, we first design a protocol to rectify these problems and then use the protocol to identify 
and compare human and chimp PSGs. Our results show substantively more PSGs in chimpanzee 
evolution than in human evolution.  
Results and Discussion 
Study Design 
To compare human and chimp PSGs impartially, we made three improvements in the design of 
the analysis. First, to distinguish nucleotide substitutions that occurred in the human lineage from 
those that occurred in the chimp lineage, we used the macaque monkey as the outgroup. Because 
the divergence time between the macaque and human/chimp is approximately a quarter of that 
between the mouse and human/chimp (Goodman et al. 1998; Hedges 2002; Glazko and Nei 
2003), the reliability of our analysis was expected to increase significantly. Gene orthology 
determination and sequence alignment among the more closely related human–chimp–macaque 
gene trios is also more reliable than among human–chimp–mouse trios.  
Second, we applied an improved branch-site likelihood method for identifying PSGs (Zhang et al. 
2005), which has been shown by computer simulation to produce good results even when some of 
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the assumptions are violated (Zhang et al. 2005). The method requires that the branches in a 
phylogenetic tree be separated into foreground and background branches a priori, where 
foreground branches are tested for the occurrence of positive selection. The method assumes that 
two classes of codons, either negatively selected (class 0) or neutral (class 1), exist in the 
background branches. This null model is compared with an alternative model in which a 
proportion of class 0 codons, and the same proportion of class 1 codons, become positively 
selected in the foreground branches. Positive selection in foreground branches is inferred for a 
gene if the likelihood of the observation of the gene sequences is significantly higher under the 
alternative model than under the null model. To further verify the suitability of the method in the 
present context, we conducted additional computer simulations specifically designed to mimic the 
evolution of human, chimp, and macaque genes (see Materials and Methods). Our results showed 
that the false-positive rate is acceptable, except for extreme conditions when it slightly exceeds 
the nominal rate (Table 3.3 and Table 3.4).  
Third, we used high-quality nucleotides from the 4X coverage chimp genome sequence to allow a 
fair comparison with the human sequence. Briefly, we assembled alignments of orthologous 
genes from human, chimp, and macaque, using publicly available genome sequences and 
annotations (see Materials and Methods). We then eliminated alignment gaps and those codons in 
which one or more chimp nucleotides did not meet our quality cutoff. Three different cutoffs, low 
(Q0), intermediate (Q10), and high (Q20), were used to generate three data sets. After removing 
alignments of <100 codons, we obtained our final data sets, containing 13,955, 13,924, and 
13,888 genes for the Q0, Q10, and Q20 cutoffs, respectively (Table 3.5). Even the smallest data 
set (Q20) has a total alignment length of 17,995,887 nucleotides, with a mean alignment length of 
432 codons (standard deviation, 339 codons). All three data sets contain >50% of genes in a 
primate genome and cover >50% of all protein-coding regions in the genome. Using parsimony, 
we inferred the numbers of nucleotide substitutions in human and chimp lineages since their split. 
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This inference is expected to be accurate because the three species studied here are closely 
related. We found that the ratio of the number of synonymous substitutions in the chimp lineage 
to that in the human lineage is r = 1.103 ± 0.009, 1.020 ± 0.008, and 0.985 ± 0.008 for the Q0, 
Q10, and Q20 data sets, respectively. Assuming identical mutation rates per year between human 
and chimp lineages, r is expected to be 1. If the mutation rate is 3% lower in humans than in 
chimps, as has been suggested (Elango et al. 2006), r is expected to be 1.03. Given these 
considerations, Q0 data, as used in an earlier study (Arbiza et al. 2006), are apparently unsuitable 
because the observed r is significantly higher than the expectation. To make our conclusion more 
conservative, we use Q20 rather than Q10 data. Two other independent assessments of the chimp 
genome sequence, one of which evaluated it against 172 kb of finished chimp sequence, also 
recommended the use of Q20 data for comparison with the human genome sequence (Consortium 
2005; Taudien et al. 2006). Most importantly, the number of synonymous substitutions is already 
1.5% lower in chimp than in human when the cutoff of Q20 is used, suggesting that the chimp 
sequencing errors become negligible at this quality level. The comparison between the 172 kb of 
draft and finished chimp sequences also showed that the use of cutoffs higher than Q20 is 
undesirable because many chimp-specific nucleotide changes tend to be lost (Taudien et al. 
2006). This is probably because polymorphic sites in the chimp individual that was sequenced, 
estimated to be 0.1% of all sites (Consortium 2005), tend to have lower qualities than 
homozygous sites. These polymorphic sites are excluded progressively as one increases the 
quality cutoff, which hampers a fair comparison with human because the human genome 
sequence contains polymorphic sites (Consortium 2005). Note that errors in the macaque genome 
sequence should not affect our analysis because the probability for a macaque error to occur at a 
nucleotide position where human and chimp differ is small. Even when such rare events occur, 
they should affect human and chimp equally and hence would not bias our results. Our human–
chimp comparison should not be biased by indel errors because the detection of positive selection 
does not use indel information.  
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More PSGs in Chimp Evolution than in Human Evolution 
Applying the likelihood method and a P value of 5% for statistical significance (Zhang et al. 
2005), we identified 154 genes that were under positive selection in the human lineage (Table 3.1 
and Appendix) and 233 in the chimp lineage (Appendix). Thus, chimps have 51% more PSGs 
than humans have. As expected, the excess of chimp PSGs is even greater (157%) should the Q10 
data be used (Table 3.5). The proportion of PSGs in the genome is 233/13,888 = 1.7% for the 





 test). Because 13,888 statistical tests were conducted for each lineage, it is necessary to 
control for multiple testing. Under Bonferroni correction, two human genes and 21 chimp genes 
remain statistically significant (Appendix). With use of a false discovery rate of 5%, the same two 
human genes and 59 chimp genes are significant (Appendix). The proportion of PSGs in the 





even after the multiple-testing corrections (Table 3.1).  
To further confirm our results, we analyzed the recently released 6X chimp genome assembly for 
the 233 chimp PSGs identified above. We found that 212 (or 91%) of them still show significant 
signals of positive selection (see Materials and Methods). Hence, when this new data set is used, 
chimps have 38% more PSGs than humans have (P = 0.002, χ
2
 test). Note that this is a 
conservative estimate because we did not consider non-PSGs from the 4X sequence that may 
become PSGs in the 6X sequence. Such incidences are possible because potentially more 
nucleotides per gene can be analyzed in the 6X sequence, leading to improved statistical power in 
identifying PSGs. Additionally, 4X and 6X sequences may differ at polymorphic sites, which can 
affect the outcome of PSG identification when the number of substitutions is small. Because the 
analyses of the 4X and 6X sequences both indicate substantially more PSGs in chimps than in 
humans, and because the 6X assembly is preliminary and unpublished, our subsequent analyses 
use the PSGs identified from the Q20 data of the 4X assembly. An additional reason for using the 
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4X assembly is the finding of a number of cases in which the 4X assembly is apparently more 
accurate than the 6X assembly (see Materials and Methods).  
We found that the mean ω of all genes is 0.259 ± 0.002 in the human lineage, significantly larger 
than that (0.245 ± 0.002) in the chimp lineage (P < 10
-4
; Table 3.1). For the common set of 13,508 
non-PSGs between humans and chimps, the mean ω is also significantly larger in human (0.252 ± 
0.002) than in chimp (0.238 ± 0.002) (P < 10
-4
; Table 3.1). Because the majority of non-PSGs are 
under negative selection, as reflected in their low ω values, the above results indicate stronger 
negative selection in chimps than in humans. Multiple-population genetic data indicate that the 
long- term effective population size of humans (in the last 1–2 million years) is several-fold 
smaller than that of chimps and than that of the human–chimp common ancestor ((Ferris et al. 
1981; Takahata et al. 1995; Ruvolo 1997; Kaessmann et al. 1999; Chen and Li 2001; Kaessmann 
et al. 2001; Stone et al. 2002; Wall 2003; Fischer et al. 2004)). A recent analysis of 1 million base 
pairs of Neanderthal nuclear DNA also suggested that the common ancestor of modern humans 
and Neanderthals had a small effective population size (Green et al. 2006). It is thus probable that 
the effective population size is greater in the chimp lineage than in the human lineage for a large 
portion of the divergence time between the two lineages. Population genetic theories (Kimura 
1983b) predict that both positive and negative selection are more effective in large populations 
than in small populations. Our observation that chimps have more PSGs but fewer 
nonsynonymous substitutions in non- PSGs than humans is consistent with these predictions.  
Computer simulations showed that the branch-site likelihood method cannot detect all PSGs. 
Rather, the detection rate increases as the ω of background branches increases (Table 3.6). If the 
overall strength of positive selection is weaker in humans than in chimps because of smaller 
populations of humans than chimps, a higher average background ω is required for PSGs to be 
detectable in humans than in chimps. We found that in the macaque branch of the human–chimp–
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macaque tree, the mean ω for all genes is 0.226±0.001. For human PSGs, the mean ω in the 
macaque branch is 0.294 ± 0.007, significantly greater than the mean ω in the macaque branch 
(0.278±0.005) for chimp PSGs (P<0.05). Hence, these observations are consistent with the 
simulation result and further support the notion that positive selection was weaker in the human 
lineage than in the chimp lineage. Theories also predict that recombination can increase the 
efficacy of selection (Hill and Robertson 1966). Indeed, PSGs tend to be located in high-
recombination regions, although this effect is significant in chimps (P = 0.041) but not in humans 
(P = 0.32) (Figure 3.7), probably as a result of a difference in statistical power caused by the 
difference in the number of PSGs in the two species. 
Similarities and Differences Between Human and Chimp PSGs 
It has been claimed that genes of certain functional categories, such as olfaction and nuclear 
transport, were more frequently under positive selection in humans than in chimps, based on the 
ranking of all genes by their P values in the likelihood test of positive selection (Clark et al. 
2003). Because genes with reduced negative selection also tend to have low P values (although 
unlikely to be as low as 0.05), such ranks potentially mix genes under positive selection with 
those under reduced negative selection. We took a more rigorous approach by limiting our 
analysis to the PSGs we detected. We found that seven genes are shared between the human and 
chimp PSGs (Table 3.7), significantly greater than expected by chance (2.6; P < 0.02, binomial 
test), suggesting the presence of some common targets of positive selection in the two lineages. 
We classified all PSGs into biological process groups and molecular function groups, as defined 
in the PANTHER database (Mi et al. 2005). A randomization test indicated a significant 
difference in distribution of human and chimp nonoverlapping PSGs among biological process 
groups (Figure 3.1A) and among molecular function groups (Figure 3.1B). Those groups showing 
the greatest differences between the two species are listed in Figure 3.1C. Interestingly, however, 
the majority of these groups (e.g., protein metabolism and modification, anion transport, 
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phosphate transport, and lyase) do not correspond to the widely assumed adaptive phenotypic 
differences between humans and chimps (e.g., neurogenesis), suggesting the existence of yet-to-
be-recognized adaptive phenotypic differences between the two species. We did not detect 
several previously reported PSGs that control brain size or cognitive functions (Enard et al. 
2002b; Zhang et al. 2002; Zhang 2003; Evans et al. 2004b) because previous identifications of 
these PSGs were based on a comparison of polymorphism and divergence data, whereas only 
divergence data are used here. As mentioned above, due to the paucity of chimp polymorphism 
data, any fair genomewide comparison of human and chimp PSGs would have to be limited to 
divergence data at this time.  
Using microarray data of human gene expression, we found that human and chimp PSGs are not 
significantly different in their distributions between the categories of tissue-specific genes and 
nonspecific genes (P > 0.5, χ
2
 test; Table 3.8). On examining the peak-expression tissue group for 
each gene (Appendix), we again found no significant difference in the overall tissue distribution 
between human and chimp PSGs (Figure 3.2). Notably, 14 (11%) human PSGs and 13 (6.7%) 
chimp PSGs have peak expressions in one or more parts of the brain, but the difference is not 
statistically significant (χ
2
 = 1.74, P = 0.19). On the contrary, for the central nervous system 
outside of the brain, human (8) has fewer PSGs than chimp (14) (χ
2
 = 0.09, P = 0.77). These 
findings are consistent with recent comparative genomic analyses (Shi et al. 2006; Wang et al. 
2007) and do not support more positive selection in humans than in chimps in regard to nervous 
system genes (Dorus et al. 2004).  
Genome-wide identification of human and chimp PSGs helps to test several evolutionary 
hypotheses. First, it has been argued that PSGs are more likely than non-PSGs to underlie known 
Mendelian disorders in humans because the current environment of humans is considerably 
different from that of earlier hominins and previous adaptive changes may become deleterious 
today (Neel 1962; Young et al. 2005). Our data provide some support for this hypothesis. We 
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found that 9.7% of human PSGs are disease-associated (Appendix), significantly greater than that 
(6.1%) among the non-PSGs examined (P = 0.049; Table 3.2). Consistent with the prediction of 
the above hypothesis, the fraction of human PSGs underlying human diseases is greater than the 
fraction of chimp PSGs underlying human diseases (P = 0.044, Fisher’s exact test). Furthermore, 
as expected, there is no significant difference in the proportion of genes underlying human 
diseases between chimp PSGs and non-PSGs (P = 0.23; Table 3.2).  
Second, a recently proposed chromosomal speciation hypothesis asserts that chromosomal 
rearrangements facilitated the formation of reproductive isolation between populations that 
eventually led to modern humans and chimps (Navarro and Barton 2003). Several predictions of 
this hypothesis have been examined, with mixed results (Lu et al. 2003; Navarro and Barton 
2003; Marques-Bonet et al. 2004; Zhang et al. 2004; Osada and Wu 2005; Innan and Watanabe 
2006; Patterson et al. 2006). One interesting prediction that has not been explicitly tested is that 
PSGs are preferentially located on rearranged chromosomes because such chromosomes are less 
likely to be introgressed after the initial separation of two lineages during speciation and thus are 
more likely to accumulate genes subject to local adaptations (Navarro and Barton 2003). Nine 
chromosomes (1, 4, 5, 9, 12, 15–18) contain pericentric inversions between humans and 
chimpanzees, and human chromosome 2 resulted from a fusion of two acrocentric chromosomes 
common to other great apes (Yunis and Prakash 1982). These chromosomes are considered as 
rearranged chromosomes, whereas the other chromosomes are considered as colinear 
chromosomes. Our data, however, do not support the chromosomal speciation hypothesis for 
humans and chimps because the proportion of PSGs is even slightly lower on the rearranged 





In summary, our genome-wide analysis showed that substantively more genes underwent positive 
selection in the chimp lineage than in the human lineage since their split. Although our study 
could not, and did not, detect all PSGs in human and chimp evolution, particularly those 
beneficial alleles that are yet to be fixed (Bustamante et al. 2005; Sabeti et al. 2006; Wang et al. 
2006), it provides an unbiased comparison between the two lineages. Our results have several 
implications. First, in sharp contrast to common belief, there were more adaptive genetic changes 
during chimp evolution than during human evolution. Without doubt, we tend to notice and study 
human-specific phenotypes more than chimp-specific phenotypes, which may have resulted in the 
prevailing anthropocentric view on human origins. Our finding suggests more unidentified 
phenotypic adaptations in chimps than in humans. Although human and chimp PSGs show 
different distributions among molecular functions and biological processes, the differences do not 
ostensibly correspond to the widely assumed adaptive phenotypes in humans. Assuming that our 
statistical method is equally powerful in detecting PSGs of different biological processes, the 
finding shows how little is currently known about which traits are adaptive. Second, although the 
influence of population size on negative selection has been well documented (Ohta 1995; Eyre-
Walker and Keightley 1999), the present study also demonstrates the impact of population size on 
positive selection at the genomic scale. Interestingly, even during human evolution when so many 
apparently dramatic phenotypic changes took place, the laws of population genetics prevailed. 
This being said, it is important to recognize that other factors also influence the frequency of 
positive selection. For example, it is possible that as a result of the relatively recent out-of-Africa 
migration of modern humans, many new advantageous alleles are yet to be fixed and thus are not 
identified by our method. Our results thus apply largely to completed selective sweeps in human 
and chimp lineages. Furthermore, a higher level of polymorphism in chimps than in humans 
could potentially lead to more predicted PSGs in chimps than in humans. But because some 
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chimp polymorphic sites have been removed in the Q20 data, and because the number of 
synonymous changes is already 1.5% lower in chimp than in human for the Q20 data, we do not 
think this factor has affected our result. At any rate, it will be interesting to examine in other 
species whether the number of PSGs is strongly dependent on population size. Third, although we 
only studied positive selection on protein sequence changes and did not address positive selection 
on gene expression evolution (Rockman et al. 2005; Khaitovich et al. 2006), a recent comparison 
between hominoids and murids in regard to regulatory sequence conservation showed that a 
reduction in population size also lowers the efficiency of natural selection on gene expression 
changes (Keightley et al. 2005). Most interestingly, when conserved noncoding sequences, which 
often regulate gene expression, are examined, chimps show more incidences of accelerated 
evolution than humans do (Prabhakar et al. 2006). Thus, it is likely that the total number of genes 
for which either the regulatory or coding regions underwent adaptive selection is also greater in 
chimp evolution than in human evolution. 
Materials and Methods 
Compilation of Human–Chimp–Macaque Gene Sequence Data 
Protein and corresponding nucleotide sequences of all predicted genes in the human, chimpanzee, 
and macaque genome sequences were downloaded from Ensembl (version 36, December 2005; 
www. ensembl.org). To identify orthologous genes, human protein sequences (n = 33,869) were 
used to conduct BLASTP searches (Altschul et al. 1990) against the chimpanzee (n = 39,648) and 
macaque (n = 31,371) protein sequences. Reciprocal searches were performed using the 
chimpanzee and macaque proteins to query the human proteins. A total of 19,422 proteins with 
reciprocal best hits in both human/ chimpanzee and human/macaque searches were retained for 
further analysis. Alignment of the human–chimpanzee–macaque orthologous proteins was 
performed using CLUSTALW version 1.83 (Thompson et al. 1994). DNA sequence alignments 
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were obtained by following the protein sequence alignments. Alignments containing <100 amino 
acids (n = 1,291) were discarded. Lineage-specific nucleotide substitutions were identified by 
parsimony as described in the next paragraph. Review of several alignments that had 
exceptionally high proportions of human- or chimpanzee-specific changes revealed that the 
apparent high level of lineage-specific changes resulted from incorrect alignment or 
nonorthology. Therefore, alignments containing >10% human- or chimpanzee-specific amino 
acid or nucleotide changes or >30% macaque-specific changes (n = 161) were discarded from 
analysis. Finally, each protein was assigned to a gene on the basis of the Ensembl annotation, and 
the protein sequence with the longest amino acid alignment was retained for each gene, resulting 
in the alignments of human, chimpanzee, and macaque sequences of 13,955 distinct genes (Q0 
data set). Chimp genome sequence quality information was downloaded from the University of 
California, Santa Cruz, Bioinformatics web site (http://hgdownload.cse.ucsc.edu/ 
goldenPath/panTro1/bigZips/chromQuals.zip). The average chimp quality score in the Q0 data set 
is 48.9526. The 13,955 alignments were scanned for codons in which one or more nucleotides 
had a chimp quality score <20 (i.e., an error rate of 1%) (Ewing et al. 1998), and these codons 
were removed from the alignments. After this procedure, 67 alignments contained <100 amino 
acids and were removed from analysis. The remaining 13,888 alignments constituted the Q20 
data set. The average chimp quality score in the Q20 data set is 49.3443. We similarly obtained 
the Q10 data set (i.e., a maximum error rate of 10% at any nucleotide site), comprising 13,925 
genes. The average chimp quality score in the Q10 data set is 49.0695.  
We applied the parsimony principle to identify human-specific and chimpanzee-specific 
substitutions, using the macaque as the outgroup. The numbers of synonymous (s) and 
nonsynonymous (n) nucleotide substitutions in the human and chimp lineages were counted. 
Using the modified Nei–Gojobori method (Zhang et al. 1998) with a transition/transversion ratio 
of 2 (Rosenberg et al. 2003), we estimated that the total number of nonsynonymous sites in the 
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13,888 genes of the Q20 data set was N = 12,783,034 and the total number of synonymous sites 
was S = 5,215,415, with their ratio being N/S = 2.45. Thus, for a set of genes, the mean 
nonsynonymous-to-synonymous rate ratio in a lineage can be computed by (n/s)/(N/S) = 
(n/s)/2.45 = 0.41n/s. 
Identification of PSGs 
Using PAML (Yang 1997), we applied the improved branch-site test of positive selection (test 2 
in ref. 25) to identify putative cases of positive selection in the human lineage among the 13,888 
genes (Q20 data). When we tested positive selection in the human lineage, the human branch was 
designated as the foreground branch and the chimp and macaque branches were designated as 
background branches. We tested positive selection in the chimp lineage similarly. Bonferroni 
correction (Sokal and Rohlf 1995) and a false discovery rate of 5% (Storey and Tibshirani 2003) 
were used to correct for multiple testing. We also analyzed the Q10 data set and identified 165 
human and 424 chimp PSGs.  
Comparison Between Human and Chimp PSGs 
Using the PANTHER database (Mi et al. 2005), we classified the 13,888 genes into different 
groups of biological processes and molecular functions. Note that these groups are not mutually 
exclusive and that a gene may belong to more than one group. To examine the distributional 
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where xi and yi are the number of human and chimp PSGs, respectively, in PANTHER group i, 
and n is the total number of PANTHER groups. Because of the nonindependence of PANTHER 
groups, we used a randomization test to examine whether the observed χ
2
 was significantly 
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different from the random expectation. Briefly, we randomly divided the 373 unshared human 
and chimp PSGs into 147 human PSGs and 226 chimp PSGs and computed χ
2
 by using the above 
formula. We repeated this procedure 10,000 times to obtain the null distribution of χ
2
, to which 
the observed χ
2
 is compared. Similar results were obtained when the seven shared PSGs were 
included.  
The microarray gene expression data in 79 human tissues, and the nucleotide sequences for 
27,215 probe sets on the array, were obtained from (Su et al. 2004). The probe set sequences were 
used to perform BLAST searches against the human coding sequences annotated by Ensembl. 
Probe sets that matched to multiple genes were considered ambiguous and were discarded. A total 
of 26,195 probe sets were unambiguously matched to 16,605 distinct genes. Among these 16,605 
genes, 12,099 genes, including 127 human PSGs and 195 chimp PSGs, can be found in our Q20 
data set. For genes that matched to more than one probe set, the expression levels measured by 
different probe sets were averaged for each tissue replicate. Two replicates were available for 
each tissue, and these were averaged to determine the expression level of a gene in each tissue. 
Identification of tissue specificity can be obscured if multiple tissues with very similar expression 
profiles are used (Winter et al. 2004). We therefore consolidated multiple tissues representing 
similar areas into tissue groups and took the highest expression level from any tissue in a group as 
the single representative expression level score for the tissue group (Shi et al. 2006) (Table 2.3). 
Expression levels in pathogenic tissues were not considered. A gene was considered to be tissue-
specific if the expression level in the highest tissue group was greater than or equal to twice the 
expression level in the second highest tissue group. The 3,299 genes meeting this criterion are 




Online Mendelian Inheritance in Man (www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM) was 
used to identify all genes known to be involved in human Mendelian diseases. The chromosomal 
locations of all genes were obtained from Ensembl.  
Recombination rate data for 1-megabase segments of human chromosomes were downloaded 
from University of California, Santa Cruz (http://genome.ucsc.edu/cgi-bin/hgTables). A 
recombination rate was assigned to each gene in the Q20 data set, based on the 1-megabase 
segment in which the midpoint of the gene lies. Of the 13,888 genes analyzed here, 13,714 are 
found in regions of known recombination rates. Among these 13,714 genes, 152 human and 228 
chimp PSGs have available recombination rates. We then computed the mean recombination rate 
of the 152 human PSGs. To estimate the expected value of this mean, we randomly picked 152 
genes from 13,714 genes and computed the mean. This procedure was repeated 10,000 times to 
estimate the probability that the observed mean is greater than the expected mean. The same 
procedure was applied to chimp PSGs, under the assumption that the recombination rate of a 
chimp gene is the same as for its human ortholog, which is probably correct for the majority of 
genes at the 1-megabase scale (Serre et al. 2005). 
Use of the 6X Chimp Genome Assembly 
The 233 chimp PSGs identified by using the Q20 data from the 4X chimp sequence were 
reanalyzed using sequences from the 6X chimp genome assembly (panTro2; 
www.genome.ucsc.edu). The 6X sequences corresponding to 4X sequences of the 233 PSGs were 
found by using BLAT (http://genome.ucsc.edu/cgi-bin/hgBlat?command=start). Codons with one 
or more bases having a quality score less than Q20 in the 4X assembly were eliminated, as 
described in Materials and Methods. Of the 233 PSGs, 100 had a perfect match between the 4X 
and 6X assemblies. Forty-eight PSGs were aligned to the 6X assembly with no gaps, but with 
mismatches of 0.02-0.13%. Eighty-five PSGs were aligned to 6X with some gaps, ranging from 
0.02 to 63.0%. Codons having one or more bases missing or ambiguous (i.e., N) in the 6X 
41 
 
assembly were also eliminated, and the resulting sequence was aligned to the human and 
macaque sequences. This alignment was used in the branch-site test of positive selection in the 
chimp branch, as described in Materials and Methods. 
Of the 48 PSGs with no gaps, 42 still show positive selection in chimp, using the 6X sequence, 
whereas 6 no longer show the signal of positive selection. Of the 85 PSGs with gaps, 65 still 
show positive selection in chimp, whereas 20 appeared not to be under positive selection when 
the 6X alignment was used. Each of these 26 (6 + 20) apparent reversals was examined manually 
to determine the source of discrepancies between the 4X and 6X results. In five cases (all with 
gaps), it was determined that the 4X assembly was more accurate because of elimination of exons 
or other problems in the 6X assembly. In these cases, the 4X result was retained. 
Performance of the Improved Branch-Site Likelihood Method 
Although there have been concerns about the performance of the likelihood method in detecting 
positive selection (Nei 2005), the improved branch-site likelihood method was previously shown 
by computer simulations to produce reasonably good results, even when some of the assumptions 
are violated (Zhang et al. 2005). To further verify the suitability of the method when the number 
of substitutions is as small, as in the present context, we conducted additional simulations 
specifically designed to mimic the evolution of human, chimp, and macaque genes. The 
simulation procedure follows ref. 2. A tree of three taxa was used. The numbers of synonymous 
substitutions per site for the human, chimp, and macaque branches were set as 0.006, 0.006, and 
0.058, respectively, because these were the actual numbers observed from our Q20 data for the 
three branches. Because the 13,888 alignments have a mean length of 432 codons and a standard 
deviation of 339 codons, we examined three different sequence lengths (150, 400, and 1,000 
codons) in the simulation. To examine the type I error (i.e., false-positives), we used model B1 
(negative selection) to simulate sequence evolution in the background branches (macaque and 
chimp branches) and either model F1 or F2 for the foreground branch (human branch) (Table 
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3.3). Note that F1 and F2 do not contain sites under positive selection; rather, they represent 
partial and complete relaxation of negative selection, respectively. After the three sequences were 
generated, the likelihood method was used to detect positive selection in the human branch. 
Positive selection was inferred if the likelihood of the alternative model was greater than that of 
the null model at the 5% significance level. Four hundred simulation replications were conducted. 
The results showed that the type I error is lower than the nominal rate of 5% in the case of partial 
relaxation of negative selection (Table 3.4). In the case of complete relaxation of negative 
selection, the error rate is lower than, close to, and higher than the nominal rate for short, 
intermediate, and long sequences, respectively (Table 3.4). Because only 10% of our 13,888 
genes have >800 codons, and because complete relaxation of negative selection is rare, it is 
expected that the slightly-higher-than-nominal type I error observed in one condition of the 
simulation will have only a minimal influence on our results. Although the χ
2
  approximation of 
the likelihood ratio test depends on the large-sample assumption, our simulation showed that the 
approximation is justified in the present context. This may be due to two factors. First, we used 
χ1
2
 instead of a 50:50 mixture of point mass 0 andχ1
2
  (Self and Liang 1987; Zhang et al. 2005), 
thus reducing type I errors. Second, the χ
2
  approximation appears insensitive to sample size, as 
was found previously (Zhang 1999). 
We also examined the power of the statistical test in four simulations, by changing the 
background and foreground models (Table 3.3). The sequence length of 400 codons was used in 
this set of simulations. The four background models (B3-B6) differ in the level of mean ω. The 
corresponding foreground models (F3-F6) also have different mean ω, but have the same level of 
positive selection. The results showed that a higher background ω increases the detection rate of 
positive selection (Table 3.6). 
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We noticed that when the likelihood ratio test provides statistical evidence for positive selection 
in a gene, the estimated ω for the positively selected sites (class 2 codons) in the foreground 
branch is often very large (e.g., >100). This appears biologically unreasonable. We examined the 
accuracy of the estimated ω by using the simulations described in the previous paragraph. We 
allowed 30% of codons to be under positive selection in the foreground branch, with a mean ω 
for these positively selected codons equal to 5 (Table 3.3). However, as shown in Table 3.6, the 
estimated ω for class 2 codons has a mean of several hundred and a standard deviation of several 
hundred among the genes in which positive selection is detected by PAML. Thus, the simulations 
showed that, although the likelihood ratio test of positive selection is reliable, the estimation of ω 
(when >1) is problematic and not trustable. For this reason, we do not present the likelihood-
estimated ω values. 
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Figure 3.1 Functional differences between human and chimp unshared PSGs. 
(A and B) Human and chimp PSGs show a significantly larger difference in distribution across 
biological process groups (A) and molecular function groups (B) than by chance (P = 0.84% and 
0.26%, respectively, one-tail randomization test). The bars show the frequency distribution of the 
χ
2
 values in 10,000 random divisions of the 373 unshared PSGs into 147 human PSGs and 226 
chimp PSGs. The arrow indicates the observed χ
2
. Here, the randomization test is superior to the 
standard χ
2
 test because the functional groups are not independent of one another, and a single 
gene may belong to more than one group. Similar results are obtained when the seven shared 
PSGs are included. (C) Biological process and molecular function groups that show the greatest 
differences between human and chimp unshared PSGs, as ranked by individual χ
2
 values. Shown 
are the groups that each contribute at least 2% of the total χ
2
 of all groups. Groups with a higher 
frequency of human PSGs than chimp PSGs are shown in red; those with a higher frequency of 




Figure 3.2 Frequency distribution of human and chimp PSGs across 20 peak expression tissue 
groups.  
The overall difference between the distributions of the two species is not statistically significant 
(χ
2
 = 23.8, df=19, P=0.21). Only smooth muscle (χ
2
 = 7.7, P = 0.0056) shows a significant 
difference in proportion of PSGs between the two species, but the significance disappears when 
multiple testing is corrected for. Pink dots show the expected distribution of PSGs when there is 





Figure 3.3 Distributions of human and chimp PSGs among chromosomes.  
Contrary to the chromosomal speciation hypothesis, PSGs are slightly less abundant on 
rearranged chromosomes than on colinear chromosomes (P = 0.10 and 0.055 for the human and 
chimp lineages, respectively, χ
2
 test). The human chromosome numbers are used. The expected 
number of PSGs on each chromosome is calculated under the assumption that the probability of a 










Figure 3.4 Distribution of human and chimp PSGs across chromosomes.  
The human chromosome numbers are used. Shown are 13,714 genes in the Q20 dataset for which recombination rate data are available. Genes 
located in segments with a recombination rate in the lowest quintile of all 1-megabase segments in the genome are colored blue; genes in the 
second, third, fourth, and fifth quintiles of recombination rate are colored green, yellow, orange, and red, respectively. A total of 152 human PSGs 
(filled diamonds) and 228 chimp PSGs (open diamonds) for which recombination data are available are shown to the right of each chromosome. 
For all genes, position along the chromosome corresponds to the midpoint of the gene. There is a weak tendency for PSGs to have higher 
































Table 3.1 Genic positive selection in human and chimp lineages since their split 
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Table 3.4 False-positive rates of the branch-site likelihood method in detecting positive selection 




Table 3.5 Basic statistics of the three datasets 
 
 






















Genomic phylostratigraphy and spurious patterns of new gene evolution 
 
Abstract 
Phylostratigraphy is a method for estimating the phylogenetic age of a gene by the distribution of 
its homologs on the tree of life. Applying this method to all genes in a species constitutes 
genomic phylostratigraphy. Gene age estimation relies on the ability to detect distant homologs 
via sequence similarity, typically by BLAST and its derivatives. In spite of the expectation that 
homologs of fast evolving genes in distantly related species tend to be missed by BLAST, a 
simulation study that considered substitution rate variation among sites discovered few errors, 
stimulating an explosive use of genomic phylostratigraphy that has led to many reports of 
differential properties of genes of different ages.  Unfortunately, the simulation study relied on 
rate heterogeneity patterns of a potentially biased set of only 14 genes. Here we reevaluate the 
accuracy of genomic phylostratigraphy with a genomic scale gene set and investigate the impact 
of its error on findings about young and old genes. We show that failure to detect distant 
homologs can generate spurious non-uniform distributions of various gene properties among age 
groups, many of which are not predicted a priori. Furthermore, phylostratigraphy also 
overestimates gene age substantially for new genes that have arisen from gene duplication 
followed by very rapid sequence evolution for 20 million years. We find that the reported large 
numbers of lineage-specific genes cannot possibly be explained by the model of gene duplication 
followed by substantive neofunctionalization. Given the high likelihood that conclusions about 




genomic phylostratigraphy are explainable by a null model of biased measurement, and in all 
cases, critical evaluation of results.   
Introduction 
Compared to old genes, young genes evolve faster (Alba and Castresana 2005), are subject to less 
purifying selection and perhaps more positive selection (Cai and Petrov 2010), are less likely to 
be associated with human disease (Domazet-Loso and Tautz 2008) or to be expressed during the 
phylotypic stage (Domazet-Loso and Tautz 2010a), are more likely to be singletons (Prachumwat 
and Li 2008), and have different codon usage (Prat et al. 2009). The studies that uncovered these 
correlates of gene age relied on phylostratigraphy (Domazet-Loso et al. 2007) or similar methods 
(e.g. lineage specificity (Cai et al. 2006) or study specific variants (Prachumwat and Li 2008)) to 
estimate gene age. Gene age is operationally defined as the time since the divergence of the most 
distantly related pair of taxa in which homologs can be found. Thus, the ability to detect distant 
homologs is critical to the correct estimation of gene age, and to the reliability of conclusions 
about the properties of young and old genes. Studies of gene age may focus on one or a few 
closely related species and classify genes unique to those species as orphan genes, or they may 
take a wider view and identify genes common to a particular clade, termed lineage specific genes. 
Whether a study focuses on very young genes (orphans) or slightly older genes (lineage specific 
genes), the accuracy of gene age estimation is paramount.  
Because detection of homologs depends on sequence similarity, and slowly evolving genes retain 
greater sequence similarity with their homologs than rapidly evolving genes of the same age, it 
has been suggested that the correlation of gene age with evolutionary rate is purely artifactual 
(Elhaik et al. 2006). Elhaik et al. simulated DNA sequences representing several taxa, all derived 
from a common ancestor, for a range of evolutionary rates and used BLAST to search for the 




sequence similarity between homologs because all simulated sequences have a homolog in each 
taxon. The inability to detect homologs results in gene age estimation error, that is, the 
assignment of an incorrect age to the gene. Error rates as high as 100% were observed, and fast 
evolving genes had the highest error rates, leading the authors to conclude that the statement that 
young genes evolve fast is a mere tautology. However, the above simulation used nucleotide 
sequences, whereas amino acid sequences allow more sensitive detection of distant homologs. In 
addition, all sites were allowed to evolve at the same rate, while in real genes some sites are more 
functionally constrained than others, resulting in rate heterogeneity among sites. BLAST search 
begins by scanning the database for high scoring words – that is, sequences of a given length (w) 
that achieve a minimum similarity score to a subsequence of the query. Therefore, the presence of 
consecutive functionally constrained sites within a sequence is expected to improve BLAST 
detection. The default word size (w) in protein BLAST is only 3, so even short stretches of 
conserved residues may improve results. A simulation study comparing gene age estimation error 
in sequences simulated with and without among site rate heterogeneity confirmed this prediction 
(Alba and Castresana 2007). Using amino acid sequences and rate heterogeneity patterns derived 
from alignments of vertebrate or bilaterian species, Alba and Castresana found that while gene 
age estimation error rates were still high in fast evolving genes, the majority of genes evolve at 
rates that are consistent with very low error rates.  
While the latter simulation study implements a more realistic model than did the former, it has 
three features that make it difficult to assess to what extent the inability of BLAST to detect 
homologs impacts the estimation of gene age. First, the rate heterogeneity patterns used were 
derived from alignments of either 7 vertebrates with a most recent common ancestor 
approximately 450MYA, or 9 bilaterians with a most recent common ancestor about 980MYA. In 
both cases, these alignments may represent slowly evolving genes, as they could not have been 




the rate heterogeneity patterns of slowly evolving genes is expected to produce BLAST results 
and gene age estimates similar to those of slowly evolving genes, i.e. low gene age estimation 
error rates and old gene ages. Second, Alba and Castresana used the rate heterogeneity patterns of 
only 14 genes for which alignments could be constructed at that time. Their results may thus 
reflect the rate heterogeneity pattern of these few genes, which may not be representative of 
genomic patterns of rate heterogeneity. Third, the rate heterogeneity patterns used reflect the 
average rate of evolution over hundreds of millions of years. One model for the evolution of 
orphan genes invokes a period of relaxed constraint, during which rapid sequence change reduces 
sequence similarity to homologs (Domazet-Loso and Tautz 2003). This model also suggests that a 
period of positive selection, as a gene acquires new function, could further reduce sequence 
similarity, resulting in the appearance of an orphan gene. After a gene has acquired its new 
function, it is expected to be subject to purifying selection and thus have a reduced evolutionary 
rate. It is not clear whether genes evolving under such a regime would differ significantly from 
genes evolving gradually in terms of their estimated gene age as no such model has been 
simulated in previous studies.  
Here, we simulate the evolution of amino acid sequences using rate heterogeneity patterns 
derived from the alignments of 6,662 genes in 12 Drosophila species. These species share a most 
recent common ancestor about 60MYA, so they may reflect both slowly evolving genes as well 
as more rapidly evolving genes that would not have been included in Alba and Castresana’s 
study. We simulate the evolution of these genes under a gradual model using rates and rate 
heterogeneity patterns estimated from these alignments, and also under models of relaxation and 
neofunctionalization that more accurately reflect models of orphan gene evolution. Thus, we are 
able to examine gene age estimation error rates for genes that should be classified as old – those 
that have been evolving gradually throughout their history – as well as error rates expected for 




of ancestral function and gain of new function. For the former, failure to detect a homolog is a 
false negative, while for the latter, detection of a homolog that diverged prior to the period of 
rapid evolution is a false positive. From these simulations, we identify factors impacting gene age 
estimation error rate. In addition, we compare the properties of genes identified as old and young 
in our simulations with those reported for old and young genes in a recent study of gene age in 
Drosophila (Domazet-Loso et al. 2007) and assess the extent to which the reported results can be 
explained by gene age estimation error. Finally, in order to assess how well current models of 
orphan gene evolution explain observed levels of lineage specific genes, we estimate the 
proportion of lineage specific genes expected to be observed when both gene age estimation error 
and true young genes are taken into account, and compare this estimate to the proportion 
observed in real genomes. 
Results 
Detection of simulated homologs by BLAST 
In our study, protein sequences were simulated for each of 11 taxa represented in the phylogeny 
shown in Figure 4.1. Each sequence derives from an ancestral sequence; thus, a homolog is 
present in all 11 taxa. This process was repeated 6,662 times for each iteration of the simulation, 
using parameters derived from 6,662 actual Drosophila group alignments, resulting in a simulated 
proteome of 6,662 amino acid sequences for each of the 11 taxa. BLASTP searches were 
conducted using the simulated D. melanogaster sequences as query and the other 10 proteomes as 
database. Because homologs are present in each of the other 10 species in this simulation, failure 
of BLAST to detect all 10 homologs when gradual evolution is simulated is considered gene age 
estimation error.  
Two variants of a simulation representing gradual evolution were conducted. First, randomly 




dataset and matching the lengths of actual Drosophila alignments were evolved using 
evolutionary rates and rate heterogeneity patterns estimated by Tree-Puzzle for those alignments, 
and indel parameters as in Alba and Castresana (2007) (main simulation). Over 10 repeats of this 
simulation, BLASTP failed to detect the most distant homolog for 11.8% of simulated proteins, 
failed to detect at least one of the 10 existing homologs for 12.2% of proteins, and failed to detect 
any homologs for 2.2% of proteins. (Table 4.1). A second simulation, identical to the main 
simulation except that actual D. melanogaster sequences were used as the ancestral sequences in 
place of the randomly generated ancestral sequences, failed to detect the most distant homolog for 
10.9% of simulated proteins, failed to detect at least one of the 10 existing homologs for 11.4% of 
proteins, and failed to detect any homologs for 2.2% of proteins. (Table 4.1).  
Since the evolutionary rate of a given site may change as selective pressures change over time, 
we also simulated sequences with a change in rate heterogeneity patterns. In this group of 
simulations, 0%, 10%, 25% or 50% of sites were randomly chosen from each protein, and the rate 
classes for these sites were shuffled on the branch indicated with the letter S in Figure 4.1. No 
indels were allowed in this group of simulations, but otherwise the methods were identical to the 
main simulation. In the 0%, 10%, 25%, and 50% simulations, BLAST failed to detect the most 
distant homolog in 9.0%, 9.5%, 10.3%, and 23.7% of proteins, respectively. The rates of failure 
to detect any homologs were 1.2%, 1.3%, 1.3%, and 1.3%, respectively, and the rates of failure to 
detect at least one of the 10 existing homologs were 9.2%, 9.8%, 10.7%, and 24.9%, respectively. 
Correlates of BLAST error 
It has been reported that young genes are shorter and evolve faster (Domazet-Loso and Tautz 
2003; Alba and Castresana 2005; Cai et al. 2006; Cai and Petrov 2010) than old genes. In 
addition, the rate heterogeneity patterns of a gene influence the ability of BLAST to detect 




Castresana 2007). The level of rate heterogeneity is quantified by the gamma distribution shape 
parameter alpha; low values of alpha indicate considerable among site variability, while high 
values of alpha indicate less heterogeneity among sites, more similar to evolution without rate 
heterogeneity. The degree of rate heterogeneity among sites is expected to be negatively 
correlated with the average evolutionary rate of the protein (Zhang and Gu 1998). The sequence 
of a gene evolving with rate heterogeneity is composed of a mosaic of variable length blocks with 
different evolutionary rates. Long blocks with low evolutionary rates are expected to have the 
highest potential for BLAST detection. Thus, we investigate the correlation of gene age 
estimation error with gene length, evolutionary rate, alpha, and length and relative rate of the 
longest, slowest evolving block in each gene.  
Evolutionary rate correlates well with gene age in the main simulation (r = -0.622, P = 0). Genes 
with the youngest ages, identified as having no homologs outside of Drosophila or insect 
lineages, tend to have the highest evolutionary rates (Figure 4.2). The distribution of evolutionary 
rates in each age class is significantly different from the genomic distribution, with those in the 
oldest age class evolving more slowly, and those in all other age classes evolving more rapidly 
(Figure 4.2, Mann-Whitney U test, p < 0.0001 for all tests after Bonferroni correction). Neither 
gene length nor alpha is well correlated with gene age in the Drosophila data set used in the 
present study (r = 0.110, P = 0 and -0.043, P = 0.0005, respectively). However, estimation of 
alpha is unreliable for high alpha (Gu and Zhang 1997). To examine the correlation between 
alpha and evolutionary rate, we ignore 44 genes with alpha > 3 and observe a positive correlation 
in the remaining 6,618 genes (r = 0.670, P = 0). Furthermore, almost all gene age estimation 
errors in the main simulation occur in the 10% of genes with highest alpha (Figure 4.3, last 
column), and alpha and gene age are correlated within this 10% of genes (r = 0.363, P = 0). 
The 6,662 Drosophila genes examined show considerable variation in the minimum rate class rmin 




stretch of amino acids in that rate class (cmax). (Figure 4.4A). gene age estimation error rates are 
very low for genes with low to intermediate rmin and intermediate to high cmax, while error rates 
are as high as 100% for genes with the highest  rmin and lowest cmax values (Figure 4.4B). 
Reproduction of reported results by gene age error 
We focus on three results reported in the initial paper that proposed the phylostratigraphy method 
(Domazet-Loso et al. 2007). First, these authors found that the proportion of genes of a particular 
age expressed in a given tissue may differ significantly from the genome wide proportion 
expressed in that tissue. Here, we also find significant differences between the genome wide 
proportion of endoderm, mesoderm and ectoderm expressed genes, and the proportion in genes of 
a specific age in our main simulation (Figure 4.5A) In the present study, significant differences 
after Bonferroni correction are only found when considering the sum of 10 runs of the simulation. 
Low sample size in individual runs of the simulation likely prevents deviations from genomic 
expression patterns in genes of a given age from attaining significance. Second, Domazet-Loso et 
al. calculated the number of novel genes arising per million years on each branch of the 
phylogeny. Interestingly, they found a peak in this rate of founder gene formation in the branch 
leading to the most recent common ancestor of Bilateria. We also calculated the rate of novel 
gene formation during each age interval in our simulated genes and surprisingly found a peak in 
the same branch leading to the bilaterian ancestor (Figure 4.5B). Finally, the authors of the 
previous work calculated the proportion of genes that were annotated with a biological process in 
each age group, and observed that this proportion was correlated with gene age. This correlation 
is also observed in the data from our main simulation (Figure 4.5C). 
Detection of homologs after rapid evolution 
Two additional classes of simulation were performed. First, we considered models of relaxation 




actual protein. The remaining sites were somewhat constrained in the 44% and 90% relaxed 
models (see Methods). Second, we considered models that feature gradual evolution as in the 
main simulation, followed by a burst of rapid evolution of 5MY, 10MY or 20MY at the location 
in the phylogeny indicated by the letter B in Figure 4.1, followed by gradual evolution under a 
rate heterogeneity pattern different from that in the first part of the simulation (see Methods). As 
these simulations represent models of relaxation and/or neofunctionalization that are proposed to 
lead to rapid sequence divergence and orphan gene formation, here we expect BLAST not to find 
all homologs. Whereas in the gradual evolution models, failure of BLAST to detect the most 
distant homolog was considered a gene age estimation error, here, failure of BLAST to detect the 
most distant homolog is consistent with orphan gene formation. Strictly speaking, after the burst 
of rapid evolution, no homologs should be detected in taxa that diverged prior to the burst, so 
detection of such homologs can be considered gene age estimation error as well. In this case, the 
age of a young gene is overestimated. Because the location of burst of rapid evolution in our 
simulation is on the branch leading to Drosophila after its divergence from honeybee, genes 
should not have hits in any of the other 10 taxa. For the 44% and 90% relaxed simulations, 
BLAST does not find a hit in any of the other 10 taxa for 4.5% and 64.5% of proteins, 
respectively. 14.6% and 96.3% of proteins have no hit in the most distant (E. coli) homolog, but 
do have hits in one or more intermediate taxa. In this case the genes would be assigned a gene age 
older than the branch on which the burst of evolution took place, demonstrating that even for true 
orphan genes, the phylostratigraphy method may incorrectly assign their age. For the 100% 
relaxed simulation, a tree topologically identical to that shown in Figure 4.1 was used, but with 
branch lengths representing taxa that diverged from Drosophila 5, 10, 20, 30, 40, 50, 75, 100, 
200, and 500 MYA. Rates of orphan gene formation after 200MY and 500MY are 97% and 99%, 
respectively (Table 4.1). After a burst of 5MY, 10MY or 20MY, the BLAST fails to detect any 





Predicting BLAST error 
In considering sources of error in any experiment, it is important to know whether the errors are 
random and merely generate noise, or if they are systematic and thus tend to bias results. In a 
computational experiment involving gene age, the use of BLAST to detect homologs introduces a 
predictable and significant source of bias. Although we know that evolutionary rate and rate 
heterogeneity patterns both contribute to gene age estimation error, predicting or estimating of the 
impact of this error in a given scenario is not trivial. For example, consider the impact of rate 
heterogeneity. In our simulations, BLAST often failed to find homologs for genes with high 
alpha. Interestingly, comparing the vertebrate and bilaterian genes used by Alba and Castresana 
to study the problem of BLAST error, the vertebrate genes have an average alpha (0.725) lower 
than average alpha in the 6,662 Drosophila gene used in the present study (0.997), while the 
bilaterian genes have a higher average alpha (1.125). We conducted additional simulations 
sampling from vertebrate and bilaterian rate heterogeneity patterns. Rates of gene age estimation 
error in the vertebrate simulation were lower than in our main simulation (8.6% vs. 11.8% unable 
to detect the most distant homolog), while the same measure in the bilaterian simulation was 
substantially higher (49.2%, Table 4.1). These findings demonstrate that gene age estimation 
error may play a much more important role in some contexts than in others, and thus that its 
specific impact must be examined on a case-by-case basis.   
Proportion of false positives among orphan genes 
Orphan genes may result from either gradual evolution and gene age estimation error, as in our 
main simulation, or by punctuated evolution and sequence divergence, as in the relaxed and burst 
simulations. Orphan genes resulting from these two processes may be considered false orphans 
and true orphans, respectively. It is interesting to know what proportion of observed orphans are 




not only the rate at which true orphans and false orphans arise, but the amount of raw material 
available for evolution in gradual and punctuated modes. The majority of existing genes in a 
genome are expected to be functionally constrained and thus evolving under the gradual model. 
The D. melanogaster genome contains ~13,600 genes (Adams et al. 2000) presumably evolving 
in this manner. We have observed that 2.2% of these are classified as orphans due to gene age 
estimation error after 377 million years (the divergence time between Drosophila and honeybee). 
Assuming constant genome size over evolutionary time, we expect gradual evolution to result in 
13,600 * 0.022 = 299 Drosophila or Diptera specific genes (false orphans). This is a conservative 
estimate because the 2.2% figure is derived from 1-to-1 orthologs found in all 12 sequenced 
Drosophila genomes, and these genes are likely evolving more slowly on average than all 
Drosophila genes.  
Considering the process by which true orphans arise, although some studies (Levine et al. 2006; 
Zhou et al. 2008; Toll-Riera et al. 2009) have identified genes formed de novo from intergenic 
sequences, the most likely source of raw material is gene duplication. It has been estimated that in 
Drosophila, 31 new duplicates arise per genome per million years, and that the half-life of these 
genes is 2.9MY (Lynch and Conery 2000). New duplicates may be lost to pseudogenization and 
deletion, or may become orphan genes, lost only in the sense that they can no longer be found in 
the genome due to a high level of sequence divergence. From the 100% relaxation model in our 
simulation, a high-end estimate of the rate at which genes may escape detection through sequence 
change within 5MY is 0.37%. Thus, the number of orphan genes arising in 5MY is equal to the 
number of recent duplicates available multiplied by this rate. The balance of genes lost during this 
5MY interval are pseudogenized or deleted. Using an iterative process (see Methods), we 
estimate that only 63 true orphan genes arise in the Drosophila lineage in 377MY since its 
divergence from honeybee. Although this number seems very low, it is understandable given the 




before becoming pseudogenized or being deleted. Given limitations on the mutation rate, only a 
few genes are able to escape in this short period of time. It is important to note that the rate of 
escape by sequence change is perhaps an overestimate as it is derived from our most extreme 
model of 100% relaxation. Furthermore, we assume that all of these 63 escaped genes acquire 
new function and are retained in the genome, although this may not be the case. Thus, 63 true 
orphans is probably an overestimate. 
After orphan gene formation, further duplication of these founder genes can result in greater 
numbers of observed orphan genes. Domazet-Loso et  al. (2007) used all-against-all BLAST of 
orphan genes to identify such expansions and found that the ratio of all Drosophila and Diptera 
specific orphans to founder genes was 1.21. Multiplying this ratio by the number of founder 
genes estimated above, we expect to observe about 299 * 1.21 = 362 false orphans and 63 * 1.21 
= 76 true orphans. Thus, the false positive rate among observed orphans is about 362/(362 + 76) = 
82.6%. With such a high false positive rate, studies examining the properties of “orphan genes” 
are largely examining the properties of false orphans, i.e., the properties of genes that escape 
BLAST detection.  
The overall proportion of observed Drosophila/Diptera specific orphan genes is 21.1% (Domazet-
Loso et al. 2007), about 6.6-fold higher than the proportion (362 + 76)/13,600 = 3.2% predicted 
here. What can explain the difference? As mentioned, our estimate of gene age estimation error 
rate may be low due to the necessarily conservative nature of genes for which a 1-to-1 ortholog 
exists in each of 12 Drosophila species, which would downwardly bias the number of false 
orphans. Another possibility is that the contribution of non-coding genomic regions to orphan 
gene formation has not been sufficiently appreciated. It has been estimated that 11.9% of new 
genes in Drosophila arise from such regions (Zhou et al. 2008). In addition, ~30% of new 
Drosophila genes are chimeric in nature, including some domains from an existing gene in 




genes may more rapidly escape from sequence similarity with their parents because only a portion 
of the gene must escape. Regardless of what other sources contribute to the catalog of orphans 
genes, it is clear that a large proportion, conservatively estimated at 362/(13600*0.211) = 12.6%, 
of orphan genes are due solely to gene age estimation error, and that the contribution of gene age 
estimation error exceeds that of the duplication followed by rapid divergence by 4.7-fold (362/76) 
or more.  
Finally, it is important to note that among retained duplicates, there may be many genes that have 
undergone significant amounts of rapid evolution, consistent with the models of radical 
neofunctionalization that have been proposed to result in the formation of orphan genes, but 
which still retain sufficient sequence similarity to be identified as homologs. Our simulations 
show that, for example, a burst of 20MY rapid evolution erases sequence similarity with all 
homologs for less than 5% of proteins (Table 4.1). If after a period of rapid evolution, a gene’s 
functions are very different from those of its homologs, it may be more correctly considered a 
“young gene”. Even between species as closely related as mouse and human, many homologs 
exhibit differences in fitness effect, which implies change in function, in the two species. 
Furthermore, change in fitness effect is correlated with protein sequence divergence (Liao and 
Zhang 2008). Although it may be debated what level of functional difference is sufficient to 
classify a gene as an orphan, genes with identifiable homologs that nonetheless have different 
functions represent a previously ignored source of error, i.e., false negatives in the search for 
young genes. 
Gene age estimation error as a null model 
Gene age estimation error alone is sufficient to produce “interesting” correlations between gene 
age and biologically important attributes of genes such as evolutionary rate and expression profile 




parsimonious scenario” to explain their finding of significant differences in expression pattern in 
genes of certain ages was a fluctuation in the adaptive tendencies of different evolutionary time 
periods, it is clear from our simulation results (Figure 4.5A) that a much more parsimonious 
explanation is available: gene age estimation error. It is imperative that results based on 
phylostratigraphy or similar methods be rigorously compared against a null hypothesis of gene 
age estimation error via simulation. However, simulation design requires careful choices about 
model parameters and negative simulation results may reflect parameter choice. Thus, to prevent 
erroneous conclusions about the properties of young and old genes, a skeptical evaluation of 
results is essential, especially for observations that may be explained by the differential ability of 
BLAST to detect homologs of different evolutionary rates. For example, the observation that 
young genes are subject to less purifying selection (Cai and Petrov 2010) is consistent with the 
expectations of BLAST artifact.  
Although plausible scenarios have been imagined for why young genes might evolve faster, be 
shorter, and be differentially expressed compared to old genes, these scenarios have arisen in the 
wake of observations that genes inferred to be young possess these characteristics, rather than as 
a priori hypotheses. It is critical that in the pursuit of new insights about patterns of gene 
evolution we evaluate our observations in the light of a nuanced understanding of the properties 
of the tools used to gather them. Computational experiments are not immune to the effects of 
biased measurement. Here, we have shown that the view of gene age has been distorted by 
viewing it through the lens of homology search by BLAST.  
Methods 
Genomic and supporting data 
Protein alignments of 6,699 1-to-1 orthologs present in 12 Drosophila species were downloaded 




et al. 2007). Protein alignments used in (Alba and Castresana 2007) provided by J. Castresana. 
Gene ontology biological process annotations were downloaded from FlyBase. Gene expression 
data of fly embryos (Tomancak et al. 2002) was obtained from www.fruitfly.org. Divergence 
dates were obtained from TimeTree (Hedges et al. 2006) (www.timetree.org). 
Rate heterogeneity and main simulation 
Rate heterogeneity patterns for each Drosophila alignment were estimated using TreePuzzle 
using the gamma distribution model with 16 rate categories. D. melanogaster-D. grimishawi 
genetic distance was also estimated by TreePuzzle. 37 genes with D. melanogaster-D. grimshawi 
distance = 0 were discarded from further analysis. For each site in the remaining alignments, the 
rate category contributing most to the likelihood was assigned. Rate heterogeneity patterns for 14 
alignments from (Alba and Castresana 2007) were similarly obtained. Amino acid frequencies in 
the remaining 6,662 alignments were calculated.  
Rose was used to simulate sequence evolution. In the main simulation (Gradual A in Table 4.1), a 
random sequence seed derived from calculated Drosophila amino acid frequencies was used as 
the ancestral sequence. Ancestor sequence length was set equal to the length of the 12 Drosophila 
alignment for each gene. Sequences were evolved according to the rate heterogeneity patterns 
estimated by TreePuzzle, and according to the tree shown in Figure 4.1. Branch lengths were 
scaled based on the D. melanogaster-D. grimshawi distance for each gene and the divergence 
times obtained from TimeTree. Following (Alba and Castresana 2007), gap insertion and deletion 
thresholds were set to 0.0001 and the PAM model of amino acid substitution was used. This 
process generated 6,662 sequences for each of 11 taxa included in Figure 4.1. The simulation was 
repeated 10 times, for a total of 6662 * 11 * 10 = 732,820 sequences in the main simulation. 
Sequences for taxon 1 (representing D. melanogaster) were queried against databases of each of 




for each protein according to the divergence date of the oldest taxon in which a BLAST hit was 
found. 
Alternate models of evolution 
A simulation was conducted using actual D. melanogaster sequences as the ancestor sequence. In 
this case, the length of the ancestor sequence is shorter than in the main simulation by the length 
of any gaps in D. melanogaster relative to the other 11 Drosophila. Otherwise, this simulation 
(Gradual B) was identical to the main simulation. Gradual B was repeated twice.  
Four simulations were conducted shuffling the rate categories of 0%, 10%, 25% or 50% of sites. 
Site to be shuffled were randomly chosen and some sites may have the same rate category after 
shuffling as before as the process was random and there are only 16 rate classes. In this model, 
Sequences were evolved as for the main simulation except that no indels or deletions were 
allowed, until the point indicated by the letter S in Figure 4.1, corresponding to the start of the 
branch ancestral to Metazoans. At this point, rate heterogeneity patterns were shuffled, and 
simulation was continued with the new rate assignments for the remaining branches of the 
phylogeny. Each of these simulations (0%, 10%, 25%, 50%) were repeated 10 times.  
Three simulations were conducted to model different levels of relaxation of constraint by 
constructing alternative rate heterogeneity patterns. In the first model (44% relaxed), for each 
gene, the lowest N rate categories were selected such that at least 10% of sites were included in 
those rate categories, and rate category N had a relative rate > 0. The average proportion of sites 
selected by this procedure was 56%. The selected sites were assigned rate category N. The 
remaining 44% of sites were assigned rate category 16, i.e., the maximum rate category for the 
gene. In the second model of relaxed evolution (90% relaxed), 10% of sites were randomly 
selected in blocks of 5 sites. These sites retained the rate categories assigned by TreePuzzle. The 




relaxed), all sites were assigned rate category 16. For each of these 3 models, simulation was 
conducted as for the main simulation, substituting he alternate rate heterogeneity patterns 
described. Each relaxation simulation was repeated 10 times. 
Three simulations were conducted to model a burst of rapid evolution (5MY, 10MY, and 20MY). 
In each of these, sequences were simulated as for the main simulation until the point indicated by 
the letter B in Figure 4.1, i.e. the point of divergence between Drosophila and honeybee. Even 
during a period of rapid evolution, we expect there is some level of constraint on the protein, or it 
would likely be lost or pseudogenized. Therefore, the sequence at this node was evolved using the 
same procedure as the 90% relaxed model for 5, 10 or 20 MY. Then, post-burst rate heterogeneity 
pattern was created by selecting a random gene from the 6,662 genes, and selecting a random 
starting point along the length of its alignment. Starting at this point, rate categories were 
assigned to the post-burst rate heterogeneity pattern for the 90% of sites that had been assigned 
rate category 16 during the burst. The 10% of sites that were evolving at their original rates 
during the burst retained those rates after the burst. Finally, the gene was evolved for an 
additional 372MY, 367MY, and 357MY in the 5MY, 10MY and 20MY burst models, 
respectively using the post-burst rate heterogeneity pattern. The burst simulation was repeated 10 
times. 
BLASTP search for homologs and age assignment was repeated for each iteration of the alternate 
model simulations as for the main simulation. 
Estimation of rates of orphan gene formation 
The number of new duplicate genes arising per genome per million years in Drosophila is 31 
(Lynch and Conery 2000). Thus, mutational input in 5MY is 31 * 5 = 155. Let A = the number of 
recent duplicates available for founder gene formation. The total number of gene lost in a 5MY 




2000) with the equation for exponential decay. These lost duplicates may be lost due to sequence 
divergence and escape. We used the rate of escape from measured in the 100% relaxed model at 
5MY (3.75x10
-3
/gene/5MY) to calculate the number of genes lost by escape (C = B * 3.75x10
-3
). 
Then, the number of genes lost to pseudogenization or deletion is D = C – B. The number of 
genes that have not been lost during this 5MY window is E = A – B. At+5MY = Et + 155. We set A0 
= 155 and iterated over 380MY. Convergence is reached fairly quickly. The convergence value of 
C represents the equilibrium number of orphan genes formed by escape per 5MY. By multiplying 
this figure by 377/5 we estimate the number of orphan genes formed in this way since the 
divergence of Drosophila and honeybee.  
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Figure 4.1 Phylogeny showing the relationships of sequences simulated in gene age study.
All sequences are simulated; the organism names simply illustrate the evolutionary distances 
involved. The branch lengths are proportional to divergence times between the indicated taxa. 
INT 1 and INT 2 do not represent actual taxa, but are evenly spaced between the divergence of 
plants and bacteria. B indicates the location of a simulated burst o
the location where evolutionary rates were shuffled.
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Figure 4.2 Distribution of genetic distance between 
of different ages.  
First panel (ALL) shows distribution for 
11 show distribution for genes in each age group (1





D. melanogaster and D. grimshawi
6,662 Drosophila genes used in the simulation; panels 1
-11). Age groups correspond to divergence 
11 in Figure 4.1. 
 





Figure 4.3 Age group within each of 10 approximately equally sized bins of increasing alpha.










































Figure 4.4 Distribution of 6,662 
gene and maximum block length of the minimum rate class (A) and 




Drosophila genes by minimum evolutionary rate class for the 






Figure 4.5 Log-odds ratio of expression in mesoderm, ectoderm and endoderm for each age 
group compared to the average of all genes studied.  
Bonferroni corrected p-value is indicated in the table above (two-tailed-hypergeometric test) (A). 
Rate of novel gene formation per MY by age group. (B) Percent of gene with biological process 
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Table 4.1 Parameters and results for simulation models used. 
Simulation Name 
Seed 
sequence Rate heterogeneity pattehrns Indels 
 
No  hits 
at all 
No hit in one or 
more taxa 
No  hit to most 
distant 
homolog 
Gradual evolution models     
 
Gene Age Estimation Error Rates 
 
Gradual A Random 6662 alignments of 12 Drosophila Yes 2.20% 12.20% 11.80% 
 
Gradual B D. mel 
actual 
Same as Gradual A Yes  2.20% 11.40% 10.90% 
 
Switch 0% Random Same as Gradual A No  1.20% 9.20% 9.00% 
 
Switch 10% Random Same as Gradual A, 10% of sites shuffled No  1.30% 9.80% 9.50% 
 
Switch 25% Random Same as Gradual A, 25% of sites shuffled No  1.30% 10.70% 10.30% 
 
Switch 50% Random Same as Gradual A, 50% of sites shuffled No  1.30% 24.90% 23.70% 
Punctuated evolution models     
 
Orphan Formation Rates 
 
Relaxed 44% Random Same as Gradual A, with 56% at rate 1 and 
44% at rate 16 
Yes 4.50% 15.10% 14.60% 
 
Relaxed 90% Random Same as Gradual A, with 10% at normal rate 
1 and 90% at rate 16 
Yes  64.50% 98.30% 96.30% 
 
Relaxed 100% Random Same as Gradual A, with 100% at rate  16 Yes  0.10% 99.10% 99.10% 
 
Burst 5MY Random Same as Gradual A, with 5MY as for Relaxed 
90%, followed by 372MY at a different rate 
heterogeneity pattern 
No  2.70% 14.50% 13.80% 
 
Burst 10MY Random Same as Gradual A, with 10MY as for 
Relaxed 90%, followed by 367MY at a 
different rate heterogeneity pattern 
No  3.20% 15.50% 14.70% 
 
Burst 20MY Random Same as Gradual A, with 20MY as for 
Relaxed 90%, followed by 357MY at a 
different rate heterogeneity pattern 
No  4.70% 17.50% 16.30% 
Gradual evolution models with alternate rate heterogeneity patterns   
 
BLAST Error Rates 
 
Vertebrate Random sampled from 8 alignments of 7 vertebrates Yes 0.50% 9.40% 8.60% 
 






In conclusion, I want to address three themes that unite my three projects. First, I will 
discuss the opportunities for revisiting old questions when new data become available. 
Second, I will consider the challenges of inference about function and evolutionary 
history from genomic sequences, high throughput expression data, and other genomic 
datasets. Finally, I will return to the call for careful hypothesis generation coupled with 
healthy skepticism that was articulated in the discussion section of Chapter 4. 
Old questions, new data 
Darwin attributed the success of the human species to “powers of observation, memory, 
curiosity, imagination, and reason” and inferred that these powers had arisen by the 
action of natural selection (Darwin 1871) but this conclusion was disputed by Wallace. In 
Chapter 2, using genome sequences that became available over 130 years after Darwin 
and Wallace disagreed, I examined the genomic patterns of brain gene evolution and 
found no evidence of widespread acceleration of the evolution of brain-specific genes, 
disputing the findings of Dorus and coworkers (Dorus et al. 2004). However, as noted, 
my results do not rule out positive selection on a subset of genes, but simply reveal the 
overall pattern of evolution for these genes. Nonetheless, when positive selection has 
been identified in specific genes known to have severe phenotypic consequences on brain 




microcephalin (Evans et al. 2004a) lead to microcephaly and mental retardation), strong 
objections have been raised regarding the inference that positive selection in these genes 
was due to enhanced brain function or improved cognitive abilities (Nielsen 2009).  
Given this history of conflicting conclusions and interpretations, one might wonder if it is 
possible to find satisfying answers about the evolutionary history of the human brain. In 
my opinion, the best approach takes its cue from Darwin – pile on the evidence, from as 
many sources as possible. For example, objections to the proposal that positive selection 
in ASPM and microcephalin led to increased brain size included the lack of evidence that 
mutations in these genes correlate with intelligence in modern humans (Nielsen 2009). 
As much as we might shy away from the societal implications of genetic factors that 
influence intelligence, the growing number of fully sequenced human genomes and 
associated phenomic data (Durbin et al. 2010) may make it possible to identify variants in 
brain genes that are relevant to brain size and/or some measure of intelligence. Another 
emerging resource that can help us to identify functionally important variants is the 
Neandertal genome sequence (Green et al. 2010). Neandertal encephalization is close to 
that of modern humans and even greater than that of contemporaneous archaic Homo 
sapiens (Stanyon et al. 1993). Although it is debated what cognitive abilities Neandertals 
possessed (e.g. (Gunz et al. 2010)), we may parsimoniously expect variants responsible 
for larger brain size to be present in Neandertal if they arose prior to the divergence of the 
two species. We may also identify additional Neandertal specific variants of genes 
involved in brain development and function that show signals of positive selection in that 
lineage. In addition, it has been suggested that because human intelligence differs in 




primate mammals have large brains and advanced cognitive capabilities (e.g. elephants), 
a phylogenomic approach examining a wide spectrum of mammals can shed light on the 
fundamental processes of brain evolution (Goodman and Sterner 2010). Initiatives such 
as the BGI “genomic zoo” (http://ldl.genomics.org.cn/page/bgi-g10k.jsp), which 
ambitiously proposes to sequence 10,000 vertebrate genomes by 2015, will provide the 
data needed to robustly implement the phylogenomic approach. By combining many 
types and sources of evidence, as Darwin did for evolution by natural selection in On the 
Origin of Species (Darwin 1859), the story of human brain evolution will become richer, 
and perhaps at some point can credibly be called a history rather than a mere story.  
Although I have focused here on the ways new data will illuminate the history of human 
brain evolution, these and similar data will no doubt also help uncover the evolutionary 
history of positive selection on other traits, in human and other lineages. In addition, it 
will be possible to extract an accounting of the origin of new genes within the vertebrate 
lineage with a previously impossible level of detail by analyzing the phylogenomic and 
population genomic resources now being constructed. This analysis can be informative 
about the processes of gene duplication and orphan gene formation studied in my Chapter 
4. Thus, new data can be used to address multiple old questions.  
Challenges of functional and evolutionary inference 
Different values of the nonsynonymous to synonymous substitution rate ratio (ω) are 
expected under different evolutionary regimes. For a protein with no impact on 
organismal fitness, fixation and loss are determined solely by genetic drift. Thus, 




ratio of their substitution rates is expected to be one. However, for a protein that does 
impact organismal fitness, nonsynonymous changes are more likely to affect the function 
of a protein than synonymous changes. Nonsynoymous changes may improve function, 
which is understood to mean that they improve the fitness of the organism carrying such 
changes, and thus rise to fixation by positive selection, increasing ω compared to the 
neutral case. Nonsynonymous changes may also destroy or decrease the function of the 
protein, thereby decreasing the fitness of the organism, and be eliminated by purifying 
selection. These fundamental principles in molecular evolution build on two even more 
fundamental principles in biology: function and fitness. With the availability of large 
amounts of sequence data and powerful programs to detect positive selection (Yang 
1997), it has been possible to catalog potential sites of positive selection without any a 
priori hypotheses about the function of such sites or their fitness effects, as for example in 
my Chapter 3. In the face of growing numbers of such reports of positive selection, it has 
been suggested that functional validation be required to link the molecular signature of 
selection to the fitness effect of the putatively selected variant (MacCallum and Hill 
2006).  
The challenges associated with measuring fitness and function are daunting. Even in 
tractable model organisms such as Saccharomyces cerevisiae, where fitness can be 
precisely assayed by competition among strains in the lab, fitness in a synthetic 
environment may not a good predictor of fitness in natural environments experienced in 
the evolutionary history of the species, the “lab-nature mismatch”. Of course, any past 
episodes of selection in a species depend on its fitness in the past environment. A study 




create a better correlation between evolutionary rate and condition-specific gene 
essentiality than in lab conditions, and thus concluded that the lab-nature mismatch 
hypothesis was incorrect (Wang and Zhang 2009). However, the study examined many 
nutritional conditions, but not other relevant aspects of environment less amenable to 
simulation, such as temperature, intra- and interspecific competition, toxins, pathogens, 
availability of water, etc. Any of these, or fluctuations in environment, may result in 
significant differences between lab fitness and fitness in the evolutionarily relevant 
environment. We are further hampered in assessing fitness by an unfortunate lack of 
information about even the present day environments experienced by wild yeast (Fay and 
Benavides 2005).  
Despite these challenges, the task of assessing fitness and function in yeast seems trivial 
by comparison to the prospects in human. Even supposing we had perfect data about 
genotype-phenotype-environment relationships for some human trait such as intelligence, 
inferring fitness or function from that data in the context of other human traits and in the 
context of cultural and physical environments might still be impossible. In general, we 
make simplifying assumptions based on apparent trait values, as did Darwin when he 
gave human intelligence, and even more specifically “articulate language”, primary credit 
for  human evolutionary success (Darwin 1871). 
Another challenge for making evolutionary inferences about fitness and function from 
molecular data derives from imperfect or nonexistent genotype-phenotype mapping. 
From first principles, nonsynonymous changes may be beneficial, deleterious, or even 




sequence data alone. Thus we infer the evolutionary process via observing the overall 
pattern of substitution in multiple lineages over multiple sites. But, because of the 
inherent stochasiticity of evolution, we can occasionally be misled by chance events. The 
levels of false positives in a test for positive selection are generally quite low (Table 3.4), 
but when false positives occur, it may be due to the chance occurrence of two 
nonsynonymous substitutions within a single codon (Mallick et al. 2009). Furthermore, 
when only one or a few sites are subject to positive selection, it is difficult to distinguish 
this from relaxation of constraint, leading to high levels of false negatives in tests for 
positive selection (Table 3.6).  
Skepticism, hypotheses, and the self-correcting nature of science 
Skepticism is a critical aspect of scientific inquiry. My analysis of the phylostratigraphic method 
and bias in the measurement of gene age emphasizes the need for more critical evaluation of 
results based on this and similar methods. Despite the publication of two simulation studies 
showing that measurement of gene age is biased, many studies were subsequently performed 
without any attempt to ascertain whether bias in measurement impacted their findings (Domazet-
Loso et al. 2007; Domazet-Loso and Tautz 2008; Prachumwat and Li 2008; Cai et al. 2009; Prat 
et al. 2009; Cai and Petrov 2010; Domazet-Loso and Tautz 2010a; Domazet-Loso and Tautz 
2010b), and thus may contain spurious results. 
Bias can take other forms in addition to measurement error. For example, the existing literature 
on a given subject may unduly influence our expectations about future findings. The conclusion 
that selection is less effective in smaller populations is uncontroversial. Reports of lower effective 
population size in humans compared to chimpanzees or the human-chimp common ancestor have 




1995; Ruvolo 1997; Kaessmann et al. 1999; Chen and Li 2001; Kaessmann et al. 2001; Stone et 
al. 2002; Wall 2003; Fischer et al. 2004). However, my finding, consistent with these prior 
findings, that both positive and purifying selection have been less efficient in the human lineage 
compared to the chimpanzee lineage, was considered a newsworthy surprise (Hopkin 2007). 
Why? Almost certainly because of an anthropocentric view of evolution, where the changes that 
have occurred in the human lineage are well studied and obvious even to non-scientists, and the 
changes that have occurred in the chimp lineage are mostly unknown. At present, 147 studies of 
positive selection in both human and chimpanzee are cataloged in ISI Web of Science, and 4,124 
in human alone, compared to only 19 studies that focus on chimpanzee alone. Careful study of 
chimpanzee traits has the potential to overturn the idea that chimpanzees have changed little since 
their divergence from humans. For example, detailed examination of the morphological and 
ontological aspects of knuckle walking in chimpanzee and gorilla revealed that this is not an 
ancestral trait, but rather evolved independently in chimpanzees and gorillas from non-knuckle 
walking ancestors. In the past, knuckle walking was considered to be an ancestral trait, so the new 
research shows that changes in locomotion have occurred in humans, chimpanzees, and gorillas. 
While I do not expect or suggest that the amount of research on chimpanzee evolution will ever 
equal that on human evolution, it is critical that we are aware of the biases inherent in the 
lopsided research agenda. 
In this dissertation, I present work that criticizes previous studies, as well as two published 
chapters (Shi et al. 2006; Bakewell et al. 2007) which have in turn been the subject of critical 
analysis by other authors (Mallick et al. 2009; Crespi et al. 2010). Each careful examination of 
data and methods may lead to further insights. Thus, I conclude that the process of scientific 
exchange, of open criticism and careful reading of the work of others, can continue to move us 








Genes (n=154) showing significant signal of positive selection in human before Bonferroni correction 





ENSG00000165659 DACH1 Dachshund homolog 1 (Dach1).  0.205 999.000 0.0000 
ENSG00000188153 COL4A5 Collagen alpha-5(IV) chain precursor.  0.205 999.000 0.0000 
ENSG00000186395 KRT10 Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) (Keratin-10) (K10).  0.154 268.730 0.0001 
ENSG00000188712 Q8NHB3_HUMAN Seven transmembrane helix receptor.  0.342 999.000 0.0001 
ENSG00000186683   0.615 999.000 0.0001 
ENSG00000147889 CDKN2A Cyclin-dependent kinase inhibitor 2A, isoform 4 (p14ARF) (p19ARF).  1.230 999.000 0.0001 
ENSG00000118298 CA14 Carbonic anhydrase 14 precursor (EC 4.2.1.1) (Carbonic anhydrase XIV) (Carbonate 
dehydratase XIV) (CA-XIV).  
0.820 999.000 0.0002 
ENSG00000180509 KCNE1 Potassium voltage-gated channel subfamily E member 1 (IKs producing slow voltage-
gated potassium channel beta subunit Mink) (Minimal potassium channel) (Delayed 
rectifier potassium channel subunit IsK).  
0.410 999.000 0.0002 
ENSG00000149054 ZNF215 Zinc finger protein 215 (BWSCR2-associated zinc-finger protein 2) (BAZ 2).  1.230 999.000 0.0003 
ENSG00000136003 NIFUN NifU-like N-terminal domain-containing protein, mitochondrial precursor (NifU-like 
protein) (Iron-sulfur cluster assembly enzyme ISCU).  
0.410 999.000 0.0003 
ENSG00000164626 KCNK5 Potassium channel subfamily K member 5 (Acid-sensitive potassium channel protein 
TASK-2) (TWIK-related acid-sensitive K(+) channel 2).  
0.051 612.830 0.0003 
ENSG00000171522 PTGER4 Prostaglandin E2 receptor, EP4 subtype (Prostanoid EP4 receptor) (PGE receptor, 
EP4 subtype).  
0.820 999.000 0.0003 
ENSG00000174948 GPR149 Probable G-protein coupled receptor 149 (G-protein coupled receptor PGR10).  0.205 999.000 0.0005 
ENSG00000163069 SGCB Beta-sarcoglycan (Beta-SG) (43 kDa dystrophin-associated glycoprotein) (43DAG) 
(A3b).  
0.137 242.742 0.0005 
ENSG00000169738 DCXR L-xylulose reductase (EC 1.1.1.10) (XR) (Dicarbonyl/L-xylulose reductase) (Kidney 
dicarbonyl reductase) (kiDCR) (Carbonyl reductase II) (Sperm surface protein P34H).  
0.205 906.960 0.0005 
ENSG00000164935 TM7SF4 Transmembrane 7 superfamily member 4 (Dendritic cell-specific transmembrane 
protein) (DC-STAMP) (IL-4-induced protein) (FIND).  
0.820 999.000 0.0005 
ENSG00000164977   0.246 999.000 0.0006 
ENSG00000119596 YLPM1 YLP motif-containing protein 1 (Nuclear protein ZAP3) (ZAP113).  0.308 774.738 0.0008 
ENSG00000166004 KIAA1731 CDNA FLJ37899 fis, clone CD34C3000314.  1.025 1.110 0.0008 
ENSG00000119431 HDHD3 haloacid dehalogenase-like hydrolase domain containing 3  0.410 999.000 0.0008 
ENSG00000185409 Q8IYB0_HUMAN  0.410 999.000 0.0009 
ENSG00000165632 TAF3 TAFII140 protein (Fragment).  0.410 999.000 0.0009 












ENSG00000165325 CCDC67  0.410 999.000 0.0012 
ENSG00000177138 FAM9B Protein FAM9B.  0.410 999.000 0.0013 
ENSG00000150347 ARID5B AT-rich interactive domain-containing protein 5B (ARID domain- containing protein 
5B) (Mrf1-like) (Modulator recognition factor 2) (MRF-2).  
0.137 999.000 0.0015 
ENSG00000092470 WDR76 WD repeat domain 76  0.410 914.069 0.0015 
ENSG00000160051 IQCC IQ motif containing C  1.640 999.000 0.0016 
ENSG00000100889 PCK2 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial precursor (EC 4.1.1.32) 
(Phosphoenolpyruvate carboxylase) (PEPCK-M).  
0.308 999.000 0.0017 
ENSG00000171227 TMEM37 Voltage-dependent calcium channel gamma-like subunit (Neuronal voltage-gated 
calcium channel gamma-like subunit) (Transmembrane protein 37).  
0.205 999.000 0.0017 
ENSG00000198935   0.410 999.000 0.0018 
ENSG00000090339 ICAM1 Intercellular adhesion molecule 1 precursor (ICAM-1) (Major group rhinovirus 
receptor) (CD54 antigen).  
0.342 156.095 0.0019 
ENSG00000152939 MARVELD2 MARVEL domain containing 2 isoform 1  0.615 526.677 0.0021 
ENSG00000186074 CD300LF NK inhibitory receptor precursor  0.547 264.084 0.0022 
ENSG00000164393 GPR111 Probable G-protein coupled receptor 111 (G-protein coupled receptor PGR20).  1.230 999.000 0.0023 
ENSG00000138029 HADHB Trifunctional enzyme beta subunit, mitochondrial precursor (TP-beta) [Includes: 3-
ketoacyl-CoA thiolase (EC 2.3.1.16) (Acetyl-CoA acyltransferase) (Beta-
ketothiolase)].  
0.410 999.000 0.0024 
ENSG00000181908 XR_000554.1  0.410 999.000 0.0027 
ENSG00000133101 CCNA1 Cyclin-A1.  0.410 663.547 0.0027 
ENSG00000187475 HIST1H1T Histone H1t (Testicular H1 histone).  2.460 999.000 0.0031 
ENSG00000164944 KIAA1429  0.308 482.855 0.0032 
ENSG00000131018 SYNE1 Nesprin-1 (Nuclear envelope spectrin repeat protein 1) (Synaptic nuclear envelope 
protein 1) (Syne-1) (Myocyte nuclear envelope protein 1) (Myne-1) (Enaptin).  
0.376 1.278 0.0033 
ENSG00000116141 MARK1 Serine/threonine-protein kinase MARK1 (EC 2.7.1.37) (MAP/microtubule affinity-
regulating kinase 1).  
0.410 404.497 0.0034 
ENSG00000143851 PTPN7 Tyrosine-protein phosphatase non-receptor type 7 (EC 3.1.3.48) (Protein-tyrosine 
phosphatase LC-PTP) (Hematopoietic protein-tyrosine phosphatase) (HEPTP).  
0.273 999.000 0.0036 
ENSG00000138658 NP_060862.2  0.513 560.568 0.0039 
ENSG00000163500   0.228 311.489 0.0040 
ENSG00000132677 RHBG Rhesus blood group, B glycoprotein  0.410 409.973 0.0041 
ENSG00000123901 GPR83 Probable G-protein coupled receptor 83 precursor (G-protein coupled receptor 72).  0.205 144.724 0.0042 
ENSG00000184574 GPR92 Probable G-protein coupled receptor 92.  0.410 256.320 0.0044 
ENSG00000104804 TULP2 Tubby-related protein 2 (Tubby-like protein 2).  0.410 999.000 0.0044 
ENSG00000196893 Q8N2W8_HUMAN  1.640 999.000 0.0047 












ENSG00000158292 GPR153 Probable G-protein coupled receptor 153 (G-protein coupled receptor PGR1).  0.308 999.000 0.0049 
ENSG00000158553 POM121L2  0.923 799.779 0.0050 
ENSG00000130508 PXDN PXDN protein (Fragment).  0.082 137.188 0.0050 
ENSG00000087301 KIAA1344  0.410 745.691 0.0052 
ENSG00000129696 NP_079391.1  0.513 392.348 0.0053 
ENSG00000130818 ZNF426 Zinc finger protein 426.  0.615 237.650 0.0054 
ENSG00000182551 ADI1 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase (EC 1.13.-.-) (Aci-reductone 
dioxygenase) (ARD) (Membrane-type 1 matrix metalloproteinase cytoplasmic tail-
binding protein 1) (MTCBP-1) (Submergence-induced protein 2 homolog) (SIPL).  
0.410 999.000 0.0055 
ENSG00000135931 ARMC9  0.820 263.934 0.0056 
ENSG00000033867 SLC4A7 Sodium bicarbonate cotransporter 3 (Sodium bicarbonate cotransporter 2) (Sodium 
bicarbonate cotransporter 2b) (Bicarbonate transporter) (Solute carrier family 4 
member 7).  
0.164 428.510 0.0057 
ENSG00000011028 MRC2 Macrophage mannose receptor 2 precursor (Urokinase receptor-associated protein) 
(Endocytic receptor 180) (CD280 antigen).  
0.176 128.163 0.0059 
ENSG00000178977 Q8NAT9_HUMAN  2.050 999.000 0.0059 
ENSG00000183005   0.957 114.349 0.0061 
ENSG00000147223 Q5JRB8_HUMAN Novel protein (Fragment).  0.410 999.000 0.0061 
ENSG00000139182 CLSTN3 Calsyntenin-3 precursor.  0.103 213.710 0.0064 
ENSG00000162723 SLAMF9 SLAM family member 9 precursor (CD2 family member 10) (CD2F-10) (CD84 
homolog 1) (CD84-H1).  
0.820 128.061 0.0065 
ENSG00000185087 NP_872368.1  1.230 999.000 0.0068 
ENSG00000133805 AMPD3 AMP deaminase 3 (EC 3.5.4.6) (AMP deaminase isoform E) (Erythrocyte AMP 
deaminase).  
0.410 181.036 0.0068 
ENSG00000164440 TXLNB Beta-taxilin (Muscle-derived protein 77) (hMDP77).  0.328 179.365 0.0070 
ENSG00000177553 Q8NDA9_HUMAN Novel protein (Fragment).  1.435 999.000 0.0070 
ENSG00000172769 OR5B3 Olfactory receptor 5B3 (Olfactory receptor OR11-239).  3.690 999.000 0.0072 
ENSG00000167987 VPS37C vacuolar protein sorting 37C  0.547 532.924 0.0072 
ENSG00000165409 TSHR Thyrotropin receptor precursor (TSH-R) (Thyroid-stimulating hormone receptor).  0.547 211.287 0.0074 
ENSG00000118600 TMEM5 Transmembrane protein 5.   999.000 0.0074 
ENSG00000160781 PAQR6 Progestin and adipoQ receptor family member VI.  0.410 184.802 0.0076 
ENSG00000036672 USP2 Ubiquitin carboxyl-terminal hydrolase 2 (EC 3.1.2.15) (Ubiquitin thiolesterase 2) 
(Ubiquitin-specific-processing protease 2) (Deubiquitinating enzyme 2) (41 kDa 
ubiquitin-specific protease).  
0.615 274.810 0.0076 
ENSG00000196476 CT096_HUMAN  1.435 108.387 0.0079 
ENSG00000197128 NP_001019767.1  0.615 204.378 0.0082 












Phosphatidylserine decarboxylase alpha chain; Phosphatidylserine decarboxylase beta 
chain].  
ENSG00000196242 OR2C3 Olfactory receptor 2C3.   999.000 0.0094 
ENSG00000137727 ARHGAP20 Rho GTPase activating protein 20  1.025 228.974 0.0103 
ENSG00000170264 NP_115556.1  0.547 163.768 0.0103 
ENSG00000197586 ENTPD6 Ectonucleoside triphosphate diphosphohydrolase 6 (EC 3.6.1.6) (NTPDase6) (CD39 
antigen-like 2).  
0.410 999.000 0.0104 
ENSG00000188996 HUS1B Checkpoint protein HUS1B (hHUS1B).  0.683 115.765 0.0115 
ENSG00000188039 NP_001007526.1  0.718 282.228 0.0117 
ENSG00000018607 ZNF221 Zinc finger protein 221.  1.025 96.486 0.0119 
ENSG00000198169 ZNF251 Zinc finger protein 251 (Fragment).  1.230 999.000 0.0119 
ENSG00000186530 XKR5 XK-related protein 5.  3.280 999.000 0.0121 
ENSG00000188683   1.640 207.826 0.0127 
ENSG00000137507 LRRC32 Leucine-rich repeat-containing protein 32 precursor (GARP protein) (Garpin) 
(Glycoprotein A repetitions predominant).  
0.820 999.000 0.0136 
ENSG00000141837 CACNA1A Voltage-dependent P/Q-type calcium channel alpha-1A subunit (Voltage- gated 
calcium channel alpha subunit Cav2.1) (Calcium channel, L type, alpha-1 polypeptide 
isoform 4) (Brain calcium channel I) (BI).  
0.205 170.058 0.0140 
ENSG00000163071 SPATA18 spermatogenesis associated 18 homolog  1.093 87.723 0.0143 
ENSG00000178966 NP_079221.1  1.640 236.525 0.0149 
ENSG00000132357 CARD6 Caspase recruitment domain-containing protein 6.  0.752 98.346 0.0150 
ENSG00000198483 ANKRD35 ankyrin repeat domain 35  0.683 147.562 0.0151 
ENSG00000146232 NFKBIE NF-kappa-B inhibitor epsilon (NF-kappa-BIE) (I-kappa-B-epsilon) (IkappaBepsilon) 
(IKB-epsilon) (IKBE).  
0.410 131.912 0.0153 
ENSG00000158258 CLSTN2 Calsyntenin-2 precursor.  0.224 94.972 0.0154 
ENSG00000102805 CLN5 Ceroid-lipofuscinosis neuronal protein 5 (Protein CLN5).  0.308 219.881 0.0158 
ENSG00000176900 OR51T1 Olfactory receptor 51T1.  0.273 111.343 0.0159 
ENSG00000129219 PLD2 Phospholipase D2 (EC 3.1.4.4) (PLD 2) (Choline phosphatase 2) 
(Phosphatidylcholine-hydrolyzing phospholipase D2) (PLD1C) (hPLD2).  
0.205 183.490 0.0167 
ENSG00000091157 WDR7 WD-repeat protein 7 (TGF-beta resistance-associated protein TRAG) (Rabconnectin-3 
beta).  
0.246 47.927 0.0168 
ENSG00000101405 OXT Oxytocin-neurophysin 1 precursor (OT-NPI) [Contains: Oxytocin (Ocytocin); 
Neurophysin 1].  
0.205 52.642 0.0170 
ENSG00000174038 NP_976044.1  3.690 4.740 0.0171 
ENSG00000182372 CLN8 Protein CLN8.  0.137 115.068 0.0175 
ENSG00000168575 SLC20A2 solute carrier family 20, member 2  0.164 143.491 0.0183 












(SCAD) (Butyryl-CoA dehydrogenase).  
ENSG00000019169 MARCO Macrophage receptor MARCO (Macrophage receptor with collagenous structure) 
(Scavenger receptor class A member 2).  
0.615 70.123 0.0196 
ENSG00000165238 WNK2 Serine/threonine-protein kinase WNK2 (EC 2.7.1.37) (Protein kinase with no lysine 2) 
(Protein kinase, lysine-deficient 2).  
0.351 999.000 0.0198 
ENSG00000182805 NP_001013756.1  1.025 999.000 0.0202 
ENSG00000197674 Q8NH68_HUMAN Seven transmembrane helix receptor.   999.000 0.0206 
ENSG00000002726 NM_001091.2 amiloride binding protein 1 (amine oxidase (copper-containing)) (ABP1), mRNA  0.293 999.000 0.0207 
ENSG00000139637 MYG1_HUMAN MYG1 protein.  0.410 166.481 0.0208 
ENSG00000105501 SIGLEC5 Sialic acid-binding Ig-like lectin 5 precursor (Siglec-5) (Obesity- binding protein 2) 
(OB-binding protein 2) (OB-BP2) (CD33 antigen-like 2) (CD170 antigen).  
 999.000 0.0214 
ENSG00000095637 SORBS1 Sorbin and SH3 domain-containing protein 1 (Ponsin) (c-Cbl-associated protein) 
(CAP) (SH3 domain protein 5) (SH3P12).  
0.234 120.546 0.0218 
ENSG00000196118 NP_001014979.1  0.205 999.000 0.0222 
ENSG00000141458 NPC1 Niemann-Pick C1 protein precursor.  0.469 47.724 0.0224 
ENSG00000189348 XP_934528.1 PREDICTED: hypothetical protein XP_934528  0.547 256.471 0.0225 
ENSG00000120875 DUSP4 Dual specificity protein phosphatase 4 (EC 3.1.3.48) (EC 3.1.3.16) (Mitogen-activated 
protein kinase phosphatase 2) (MAP kinase phosphatase 2) (MKP-2) (Dual specificity 
protein phosphatase hVH2).  
0.103 685.022 0.0227 
ENSG00000104635 SLC39A14 solute carrier family 39 (zinc transporter), member 14  0.205 116.647 0.0227 
ENSG00000008438 PGLYRP1 Peptidoglycan recognition protein precursor (PGRP-S).  2.050 999.000 0.0245 
ENSG00000086288 TXNDC3 Thioredoxin domain-containing protein 3 (Spermatid-specific thioredoxin-2) (Sptrx-2) 
(NM23-H8).  
0.615 132.598 0.0245 
ENSG00000164520 RAET1E NKG2D ligand 4 precursor (NKG2D ligand 4) (NKG2DL4) (N2DL-4) (Retinoic acid 
early transcript 1E) (Lymphocyte effector toxicity activation ligand) (RAE-1-like 
transcript 4) (RL-4).  
0.410 162.719 0.0249 
ENSG00000064042 NP_055803.1  0.205 226.199 0.0257 
ENSG00000165125 TRPV6 Transient receptor potential cation channel subfamily V member 6 (TrpV6) (Epithelial 
calcium channel 2) (ECaC2) (Calcium transport protein 1) (CaT1) (CaT-like) (CaT-
L).  
0.513 38.372 0.0269 
ENSG00000125631   3.280 4.037 0.0275 
ENSG00000140950 NP_065998.2  0.410 58.150 0.0283 
ENSG00000109674 NEIL3 Endonuclease VIII-like 3 (Nei-like 3) (DNA glycosylase FPG2).   999.000 0.0293 
ENSG00000174655   0.615 157.318 0.0294 
ENSG00000154719 MRPL39 Mitochondrial 39S ribosomal protein L39 (L39mt) (MRP-L39) (MRP-L5).  0.513 46.491 0.0301 
ENSG00000100376 CV008_HUMAN  0.820 36.569 0.0306 












ENSG00000167945 NP_001013660.1  1.640 999.000 0.0314 
ENSG00000153201 RANBP2 Ran-binding protein 2 (RanBP2) (Nuclear pore complex protein Nup358) 
(Nucleoporin Nup358) (358 kDa nucleoporin) (P270).  
0.351 133.102 0.0331 
ENSG00000062370 ZNF228 Zinc finger protein 228.  0.478 58.786 0.0338 
ENSG00000171936 OR10H3 Olfactory receptor 10H3.   999.000 0.0339 
ENSG00000088836 SLC4A11 Sodium bicarbonate transporter-like protein 11 (Bicarbonate transporter-related 
protein 1) (Solute carrier family 4 member 11).  
0.342 97.814 0.0342 
ENSG00000162745 OLFML2B olfactomedin-like 2B  0.319 70.723 0.0347 
ENSG00000180116 NP_001026918.2   178.068 0.0371 
ENSG00000182348 NP_857597.1  1.312 50.379 0.0373 
ENSG00000147804 SLC39A4 Zinc transporter ZIP4 precursor (Solute carrier family 39 member 4).  2.050 14.143 0.0392 
ENSG00000076382 SPAG5 Sperm-associated antigen 5 (Astrin) (Mitotic spindle-associated protein p126) 
(MAP126) (Deepest).  
 999.000 0.0397 
ENSG00000124568 SLC17A1 Renal sodium-dependent phosphate transport protein 1 (Sodium/phosphate 
cotransporter 1) (Na(+)/PI cotransporter 1) (Renal sodium-phosphate transport protein 
1) (Renal Na(+)-dependent phosphate cotransporter 1) (Solute carrier family 18 
member 1) (NA/PI-4)  
 999.000 0.0402 
ENSG00000082269 KIAA1411  0.273 74.664 0.0412 
ENSG00000186453 Q86W67_HUMAN  2.050 999.000 0.0414 
ENSG00000102794    999.000 0.0423 
ENSG00000189424    999.000 0.0429 
ENSG00000166801 FAM111A  2.870 999.000 0.0432 
ENSG00000083622 NP_060296.1  3.280 50.896 0.0454 
ENSG00000122490 PQLC1 PQ loop repeat containing 1  0.273 145.404 0.0463 
ENSG00000164649 CDCA7L transcription factor RAM2  0.273 151.192 0.0466 
ENSG00000104974 LILRA1 Leukocyte immunoglobulin-like receptor subfamily A member 1 precursor 
(Leucocyte immunoglobulin-like receptor 6) (LIR-6) (CD85i antigen).  
0.525 11.464 0.0486 
ENSG00000184278    999.000 0.0491 
ENSG00000162591 EGFL3 EGF-like domain-containing protein 3 precursor (Multiple EGF-like domain protein 
3) (Multiple epidermal growth factor-like domains 6).  
3.690  0.0498 
ENSG00000179750 APOBEC3B Probable DNA dC->dU-editing enzyme APOBEC-3B (EC 3.5.4.-) (Phorbolin- 1-
related protein) (Phorbolin-2/3).  
1.333   0.0498 
1 Gene descriptions downloaded from Ensembl. Blanks indicate information not available or unknown.    
2 Nonsynonymous/synonymous substitution rate ratio, computed by 0.41n /s . Blank indicates no synonymous changes.    
3 Nonsynonymous/synonymous substitution rate ratio, computed by PAML for foreground site class 2b    
4 Uncorrected p-value from likelihood ratio 
test 








Genes (n=233) showing significant signal of postive selection in chimpanzee before Bonferroni correction 





ENSG00000167522 ANKRD11 Ankyrin repeat domain-containing protein 11 (Ankyrin repeat-containing cofactor 
1).  
0.256 999.000 0.0000 
ENSG00000126822 PLEKHG3 pleckstrin homology domain containing, family G, member 3  0.492 999.000 0.0000 
ENSG00000152242 CR025_HUMAN 0.137 999.000 0.0000 
ENSG00000117713 ARID1A AT-rich interactive domain-containing protein 1A (ARID domain- containing 
protein 1A) (SWI/SNF-related, matrix-associated, actin- dependent regulator of 
chromatin subfamily F member 1) (SWI-SNF complex protein p270) (B120) (SWI-
like protein) (Osa homolog  
0.123 999.000 0.0000 
ENSG00000185727   0.205 999.000 0.0000 
ENSG00000165521 EML5 echinoderm microtubule associated protein like 5  0.252 999.000 0.0000 
ENSG00000002746 HECW1 NEDD4-like ubiquitin-protein ligase 1  0.186 999.000 0.0000 
ENSG00000198308 Q9NSI3_HUMAN 0.273 999.000 0.0000 
ENSG00000116141 MARK1 Serine/threonine-protein kinase MARK1 (EC 2.7.1.37) (MAP/microtubule affinity-
regulating kinase 1).  
0.410 999.000 0.0000 
ENSG00000091986 NP_955806.1 steroid-sensitive protein 1  0.351 999.000 0.0000 
ENSG00000147036 LANCL3 LanC lantibiotic synthetase component C-like 3  0.205 999.000 0.0000 
ENSG00000112276 BVES Blood vessel epicardial substance (hBVES) (Popeye domain-containing protein 1) 
(Popeye protein 1).  
0.273 999.000 0.0000 
ENSG00000106415 GLCCI1 glucocorticoid induced transcript 1  0.205 999.000 0.0000 
ENSG00000130227 XPO7 Exportin-7 (Ran-binding protein 16).  0.205 999.000 0.0000 
ENSG00000096401 CDC5L Cell division cycle 5-like protein (Cdc5-like protein) (Pombe cdc5- related protein).  0.164 999.000 0.0000 
ENSG00000126010 GRPR Gastrin-releasing peptide receptor (GRP-R) (GRP-preferring bombesin receptor).  0.273 999.000 0.0000 
ENSG00000100345 MYH9 Myosin-9 (Myosin heavy chain, nonmuscle IIa) (Nonmuscle myosin heavy chain 
IIa) (NMMHC II-a) (NMMHC-IIA) (Cellular myosin heavy chain, type A) 
(Nonmuscle myosin heavy chain-A) (NMMHC-A).  
0.112 211.772 0.0000 
ENSG00000129116 PALLD palladin  0.059 999.000 0.0000 
ENSG00000197996 PADI6 Peptidylarginine deiminase type VI (EC 3.5.3.15) (Peptidylarginine deiminase type 
6).  
0.246 915.618 0.0000 
ENSG00000198700 IPO9 Importin-9 (Imp9) (Ran-binding protein 9) (RanbP9).  0.816 999.000 0.0000 
ENSG00000123607 TTC21B tetratricopeptide repeat domain 21B  0.205 999.000 0.0000 
ENSG00000178662 TAIP2_HUMAN TGF-beta-induced apoptosis protein 2 (TAIP-2).  0.082 999.000 0.0000 
ENSG00000073050 XRCC1 DNA-repair protein XRCC1 (X-ray repair cross-complementing protein 1).  0.410 999.000 0.0000 
ENSG00000059588 TARBP1 TAR RNA binding protein 1  0.256 999.000 0.0000 
ENSG00000144130 NT5DC4  0.342 984.278 0.0000 












protein 140).  
ENSG00000102385 DRP2 Dystrophin-related protein 2.  0.273 999.000 0.0000 
ENSG00000125772 K1434_HUMAN 0.137 999.000 0.0000 
ENSG00000133619 NP_115923.1  0.293 379.927 0.0000 
ENSG00000136014 USP44 Ubiquitin carboxyl-terminal hydrolase 44 (EC 3.1.2.15) (Ubiquitin thiolesterase 44) 
(Ubiquitin-specific-processing protease 44) (Deubiquitinating enzyme 44).  
0.410 999.000 0.0000 
ENSG00000198171 CT116_HUMAN Protein C20orf116 precursor.  0.205 999.000 0.0000 
ENSG00000198265 HELZ Probable helicase with zinc-finger domain (EC 3.6.1.-).  0.410 999.000 0.0000 
ENSG00000166012 JOSD3  0.273 999.000 0.0000 
ENSG00000152422 XRCC4 DNA-repair protein XRCC4 (X-ray repair cross-complementing protein 4).  0.410 999.000 0.0000 
ENSG00000185834   0.820 999.000 0.0000 
ENSG00000169957 NP_078947.2  0.273 999.000 0.0000 
ENSG00000105216 LSM14A Protein FAM61A (Putative alpha synuclein-binding protein) (AlphaSNBP).  0.308 999.000 0.0000 
ENSG00000135605 TEC Tyrosine-protein kinase Tec (EC 2.7.1.112).  0.342 999.000 0.0000 
ENSG00000124496 TRERF1 Transcriptional-regulating factor 1 (Transcriptional-regulating protein 132) (Zinc 
finger transcription factor TReP-132) (Zinc finger protein rapa).  
0.308 999.000 0.0000 
ENSG00000100368 CSF2RB Cytokine receptor common beta chain precursor (GM-CSF/IL-3/IL-5 receptor 
common beta-chain) (CD131 antigen) (CDw131).  
0.492 999.000 0.0000 
ENSG00000113269 RNF130 Goliath homolog precursor (RING finger protein 130).  0.103 999.000 0.0000 
ENSG00000013503 POLR3B DNA-directed RNA polymerase III subunit 127.6 kDa polypeptide (EC 2.7.7.6) 
(RNA polymerase III subunit 2) (RPC2).  
0.117 999.000 0.0000 
ENSG00000162341 TPCN2 two pore segment channel 2  0.410 999.000 0.0000 
ENSG00000189257   0.308 999.000 0.0000 
ENSG00000166540 NP_060227.1 zinc finger protein 407  0.205 128.727 0.0001 
ENSG00000136383 ALPK3 alpha-kinase 3  0.513 325.969 0.0001 
ENSG00000182646 TMEM29  0.410 999.000 0.0001 
ENSG00000116750 UCHL5 Ubiquitin carboxyl-terminal hydrolase isozyme L5 (EC 3.4.19.12) (UCH- L5) 
(Ubiquitin thiolesterase L5) (Ubiquitin C-terminal hydrolase UCH37).  
0.410 999.000 0.0001 
ENSG00000188683   0.410 941.509 0.0001 
ENSG00000160299 PCNT Pericentrin (Pericentrin B) (Kendrin).  0.308 999.000 0.0001 
ENSG00000126337 KRTHA6 Keratin, type I cuticular Ha6 (Hair keratin, type I Ha6).  0.308 516.751 0.0001 
ENSG00000176819   0.820 999.000 0.0001 
ENSG00000152455 SUV39H2 Histone-lysine N-methyltransferase, H3 lysine-9 specific 2 (EC 2.1.1.43) (Histone 
H3-K9 methyltransferase 2) (H3-K9-HMTase 2) (Suppressor of variegation 3-9 
homolog 2) (Su(var)3-9 homolog 2).  
0.410 999.000 0.0001 
ENSG00000053524 MCF2L2 Rho family guanine-nucleotide exchange factor  0.273 999.000 0.0001 












(CAP) (SH3 domain protein 5) (SH3P12).  
ENSG00000182405 PGBD4 piggyBac transposable element derived 4  0.273 999.000 0.0002 
ENSG00000077063 CTTNBP2 cortactin binding protein 2  0.308 999.000 0.0002 
ENSG00000139625 MAP3K12 Mitogen-activated protein kinase kinase kinase 12 (EC 2.7.1.37) (Mixed lineage 
kinase) (Leucine-zipper protein kinase) (ZPK) (Dual leucine zipper bearing kinase) 
(DLK) (MAPK-upstream kinase) (MUK).  
0.410 999.000 0.0002 
ENSG00000189180 ZNF11A Zinc finger protein 33A (Zinc finger protein KOX31) (HA0946).  0.574 999.000 0.0002 
ENSG00000121101 TEX14 testis expressed sequence 14 isoform a  0.492 999.000 0.0003 
ENSG00000083168 MYST3 Histone acetyltransferase MYST3 (EC 2.3.1.48) (EC 2.3.1.-) (MYST protein 3) 
(MOZ, YBF2/SAS3, SAS2 and TIP60 protein 3) (Runt-related transcription factor-
binding protein 2) (Monocytic leukemia zinc finger protein) (Zinc finger protein 
220).  
0.246 999.000 0.0003 
ENSG00000135049 AGTPBP1 ATP/GTP binding protein 1  0.615 999.000 0.0004 
ENSG00000176225 RTTN rotatin  0.820 999.000 0.0004 
ENSG00000182898 TCHHL1 trichohyalin-like 1  0.820 999.000 0.0004 
ENSG00000101076 HNF4A Hepatocyte nuclear factor 4-alpha (HNF-4-alpha) (Transcription factor HNF-4) 
(Transcription factor 14).  
0.117 999.000 0.0004 
ENSG00000132321 IQCA IQ motif containing with AAA domain  0.234 999.000 0.0005 
ENSG00000119185 ITGB1BP1 Integrin beta-1-binding protein 1 (Integrin cytoplasmic domain- associated protein 
1) (ICAP-1).  
 999.000 0.0005 
ENSG00000080511 RDH8 retinol dehydrogenase 8 (all-trans)  0.410 999.000 0.0005 
ENSG00000171303 KCNK3 Potassium channel subfamily K member 3 (Acid-sensitive potassium channel 
protein TASK-1) (TWIK-related acid-sensitive K(+) channel 1) (Two pore 
potassium channel KT3.1).  
1.230 999.000 0.0006 
ENSG00000130595 TNNT3 Troponin T, fast skeletal muscle (TnTf) (Fast skeletal muscle troponin T) (fTnT) 
(Beta TnTF).  
0.461 63.182 0.0008 
ENSG00000117748 RPA2 Replication protein A 32 kDa subunit (RP-A) (RF-A) (Replication factor-A protein 
2) (p32) (p34).  
0.137 999.000 0.0008 
ENSG00000180104 EXOC3 Exocyst complex component 3 (Exocyst complex component Sec6).  0.410 999.000 0.0008 
ENSG00000118922 KLF12 Krueppel-like factor 12 (Transcriptional repressor AP-2rep).  0.410 999.000 0.0008 
ENSG00000056586 MNAB Membrane-associated nucleic acid-binding protein (RING finger protein 164).  0.273 492.590 0.0010 
ENSG00000172732 MUS81 Crossover junction endonuclease MUS81 (EC 3.1.22.-).  1.230 999.000 0.0010 
ENSG00000149115 TNKS1BP1 182 kDa tankyrase 1-binding protein.  0.410 999.000 0.0010 
ENSG00000113645 WWC1 KIBRA protein  0.082 375.411 0.0011 
ENSG00000159166 LAD1 Ladinin 1 (Lad-1) (120 kDa linear IgA bullous dermatosis antigen) (97 kDa linear 
IgA bullous dermatosis antigen) (Linear IgA disease antigen homolog) (LadA).  
0.205 904.548 0.0011 












(Kinase insert domain receptor) (Protein-tyrosine kinase receptor Flk-1) (CD309 
antigen).  
ENSG00000124006 OBSL1 OBSL1 protein (Fragment).  0.410 942.191 0.0012 
ENSG00000174448 STARD6 StAR-related lipid transfer protein 6 (StARD6) (START domain- containing protein 
6).  
0.820 999.000 0.0013 
ENSG00000188672 RHCE Blood group Rh(CE) polypeptide (Rhesus C/E antigens) (Rh30A) (RhIXB) (Rh 
polypeptide 1) (RhPI).  
2.050 999.000 0.0014 
ENSG00000101844 ATG4A Cysteine protease ATG4A (EC 3.4.22.-) (Autophagy-related protein 4 homolog A) 
(hAPG4A) (Autophagin-2) (Autophagy-related cysteine endopeptidase 2) (AUT-
like 2 cysteine endopeptidase).  
0.820 999.000 0.0014 
ENSG00000135164 DMTF1 cyclin D binding myb-like transcription factor 1  0.410 638.008 0.0016 
ENSG00000139508 NP_861450.1  1.230 999.000 0.0017 
ENSG00000198324 NP_653272.2  0.615 999.000 0.0017 
ENSG00000104059 K0574_HUMAN 3.280 999.000 0.0018 
ENSG00000011260 WDR50 WD-repeat protein 50.  0.820 999.000 0.0018 
ENSG00000112159 MDN1 Midasin (MIDAS-containing protein).  0.234 213.911 0.0018 
ENSG00000169105 D4ST1 Carbohydrate sulfotransferase D4ST1 (EC 2.8.2.-) (Dermatan 4- sulfotransferase 1) 
(D4ST-1) (hD4ST).  
0.205 656.829 0.0018 
ENSG00000158258 CLSTN2 Calsyntenin-2 precursor.  0.718 999.000 0.0019 
ENSG00000059804 SLC2A3 Solute carrier family 2, facilitated glucose transporter member 3 (Glucose 
transporter type 3, brain).  
0.273 714.347 0.0019 
ENSG00000108733 PEX12 Peroxisome assembly protein 12 (Peroxin-12) (Peroxisome assembly factor 3) 
(PAF-3).  
 999.000 0.0021 
ENSG00000103995 CEP152 Centrosomal protein of 152 kDa (Cep152 protein).  0.902 237.337 0.0022 
ENSG00000147081 AKAP4 A-kinase anchor protein 4 isoform 2  0.820 999.000 0.0023 
ENSG00000163527 STT3B source of immunodominant MHC-associated peptides  0.205 906.596 0.0023 
ENSG00000185927   0.410 999.000 0.0027 
ENSG00000001626 CFTR Cystic fibrosis transmembrane conductance regulator (CFTR) (cAMP- dependent 
chloride channel) (ATP-binding cassette transporter sub- family C member 7).  
0.547 421.255 0.0027 
ENSG00000133069 TMCC2 Transmembrane and coiled-coil domains protein 2 (Cerebral protein 11).  0.164 308.861 0.0028 
ENSG00000142178 SNF1LK Serine/threonine-protein kinase SNF1-like kinase 1 (EC 2.7.1.37) (Serine/threonine-
protein kinase SNF1LK).  
0.103 999.000 0.0029 
ENSG00000121486 NP_112196.2 N2,N2-dimethylguanosine tRNA methyltransferase-like  0.615 428.612 0.0031 
ENSG00000185739 SRL Sarcalumenin precursor.  1.230 999.000 0.0031 
ENSG00000181804 SLC9A9 Sodium/hydrogen exchanger 9 (Na(+)/H(+) exchanger 9) (NHE-9) (Solute carrier 
family 9 member 9).  
0.103 333.850 0.0031 












methyltransferase 3).  
ENSG00000187272 KRTAP9-9 Keratin-associated protein 9-4 (Keratin-associated protein 9.4) (Ultrahigh sulfur 
keratin-associated protein 9.4).  
0.410 19.774 0.0032 
ENSG00000184956 MUC6 Mucin glycoprotein (Fragment).  0.273 67.165 0.0034 
ENSG00000187187 ZNF546 zinc finger protein 546  0.683 208.162 0.0034 
ENSG00000138411 HECW2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2  0.256 163.790 0.0035 
ENSG00000151150 ANK3 Ankyrin-3 (ANK-3) (Ankyrin G).  0.224 721.181 0.0037 
ENSG00000187820    999.000 0.0037 
ENSG00000137871 SUHW4 suppressor of hairy wing homolog 4 isoform 1  0.615 492.176 0.0039 
ENSG00000148840 PPRC1 PGC-1 related co-activator  0.820 192.508 0.0039 
ENSG00000165164 CX022_HUMAN Protein CXorf22.  0.410 635.085 0.0040 
ENSG00000141458 NPC1 Niemann-Pick C1 protein precursor.  0.293 202.984 0.0041 
ENSG00000071203 MS4A12 Membrane-spanning 4-domains subfamily A member 12.  0.615 999.000 0.0043 
ENSG00000154783 FGD5 FYVE, RhoGEF and PH domain-containing protein 5 (Zinc finger FYVE domain-
containing protein 23).  
0.154 978.102 0.0044 
ENSG00000184950   3.280 999.000 0.0044 
ENSG00000174123 TLR10 Toll-like receptor 10 precursor.  0.246 444.812 0.0045 
ENSG00000113905 HRG Histidine-rich glycoprotein precursor (Histidine-proline-rich glycoprotein) (HPRG).  1.503 85.310 0.0045 
ENSG00000189409 MMP23B matrix metalloproteinase 23B precursor  0.273 148.851 0.0046 
ENSG00000157950 SSX2 Protein SSX2 (Synovial sarcoma, X breakpoint 2) (SSX) (HOM-MEL-40).  0.273 460.090 0.0046 
ENSG00000189136 NP_997265.1  1.640 999.000 0.0048 
ENSG00000177553 Q8NDA9_HUMAN Novel protein (Fragment).  0.615 599.959 0.0049 
ENSG00000133958 NP_065869.2  0.293 195.484 0.0049 
ENSG00000103569 AQP9 Aquaporin-9 (AQP-9) (Small solute channel 1).  0.410 300.882 0.0054 
ENSG00000198796 ALPK2 heart alpha-kinase  0.761 164.694 0.0056 
ENSG00000155275 NP_689757.1  0.615 354.045 0.0057 
ENSG00000186152 LILRB3 Leukocyte immunoglobulin-like receptor subfamily B member 3 precursor 
(Leukocyte immunoglobulin-like receptor 3) (LIR-3) (Immunoglobulin- like 
transcript 5) (ILT-5) (Monocyte inhibitory receptor HL9) (CD85a antigen).  
0.568 424.616 0.0060 
ENSG00000196427 Q5VWK0_HUMAN Novel protein similar to FLJ32883 containing DUF1220 domains (Fragment).  0.718 48.563 0.0060 
ENSG00000179698 NP_115918.1  0.273 999.000 0.0063 
ENSG00000076928 ARHGEF1 Rho guanine nucleotide exchange factor 1 (p115-RhoGEF) (p115RhoGEF) (115 
kDa guanine nucleotide exchange factor) (Sub1.5).  
0.137 176.505 0.0064 
ENSG00000096384 HSP90AB1 Heat shock protein HSP 90-beta (HSP 84) (HSP 90).  0.154 78.444 0.0066 
ENSG00000103449 SALL1 Sal-like protein 1 (Zinc finger protein SALL1) (Spalt-like transcription factor 1) 
(HSal1).  
0.342 999.000 0.0067 












ENSG00000115526 CHST10 Carbohydrate sulfotransferase 10 (EC 2.8.2.-) (HNK-1 sulfotransferase) (HNK1ST) 
(HNK-1ST) (huHNK-1ST).  
0.273 170.596 0.0067 
ENSG00000187010 RHD Blood group Rh(D) polypeptide (Rhesus D antigen) (RHXIII) (Rh polypeptide 2) 
(RhPII).  
0.718 999.000 0.0071 
ENSG00000181950 Q8NH17_HUMAN Seven transmembrane helix receptor.  2.050 999.000 0.0071 
ENSG00000172038 KV3H_HUMAN Ig kappa chain V-III region CLL precursor (Rheumatoid factor).  1.025 999.000 0.0071 
ENSG00000082213 NP_060826.1  0.137 228.823 0.0073 
ENSG00000185507 IRF7 Interferon regulatory factor 7 (IRF-7).  0.176 302.105 0.0073 
ENSG00000124731 TREM1 Triggering receptor expressed on myeloid cells 1 precursor (TREM-1) (Triggering 
receptor expressed on monocytes 1).  
 999.000 0.0073 
ENSG00000135622 SEMA4F Semaphorin-4F precursor (Semaphorin W) (Sema W) (Semaphorin M) (Sema M).  0.164 177.660 0.0074 
ENSG00000173230 GOLGB1 Golgin subfamily B member 1 (Giantin) (Macrogolgin) (372 kDa Golgi complex-
associated protein) (GCP372).  
1.312 124.825 0.0074 
ENSG00000143740 NP_444280.1  0.410 998.999 0.0074 
ENSG00000130816 DNMT1 DNA (cytosine-5)-methyltransferase 1 (EC 2.1.1.37) (Dnmt1) (DNA 
methyltransferase HsaI) (DNA MTase HsaI) (MCMT) (M.HsaI).  
0.046 164.787 0.0077 
ENSG00000184459 BPIL2 Bactericidal/permeability-increasing protein-like 2 precursor.  0.308 450.330 0.0078 
ENSG00000198946 SSX4 Protein SSX4.  0.683 999.000 0.0084 
ENSG00000163492 NP_775919.2  0.308 229.471 0.0085 
ENSG00000141690   1.230 74.633 0.0085 
ENSG00000188885   1.640 999.000 0.0086 
ENSG00000133056 PIK3C2B Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing beta polypeptide 
(EC 2.7.1.154) (Phosphoinositide 3-Kinase-C2-beta) (PtdIns-3-kinase C2 beta) 
(PI3K-C2beta) (C2-PI3K).  
0.082 152.423 0.0088 
ENSG00000183621 ZNF438 ZNF438 transcript variant 3  0.820 160.922 0.0092 
ENSG00000164151 Q6ZT40_HUMAN CDNA FLJ44990 fis, clone BRAWH3008559.  0.293 352.398 0.0094 
ENSG00000106328 FSCN3 Fascin-3 (Testis fascin).  0.410 999.000 0.0095 
ENSG00000117616 NP_064713.3  0.176 433.752 0.0099 
ENSG00000135951 TSGA10 testis specific, 10  0.820 999.000 0.0102 
ENSG00000100829 PPP1R3E Homeobox and leucine zipper protein Homez (Homeodomain leucine zipper- 
containing factor).  
0.820 215.162 0.0110 
ENSG00000134285 FKBP11 FK506-binding protein 11 precursor (EC 5.2.1.8) (Peptidyl-prolyl cis- trans 
isomerase) (PPIase) (Rotamase) (19 kDa FK506-binding protein) (FKBP-19).  
 999.000 0.0112 
ENSG00000130779 RSN Restin (Cytoplasmic linker protein 170 alpha-2) (CLIP-170) (Reed- Sternberg 
intermediate filament-associated protein) (Cytoplasmic linker protein 1).  
0.176 999.000 0.0115 
ENSG00000090512 FETUB Fetuin-B precursor (IRL685) (16G2).  0.513 497.834 0.0117 












alpha-1,2-mannosidase IB) (Alpha-1,2-mannosidase IB) (Mannosidase alpha class 
1A member 2).  
ENSG00000164588 HCN1 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 
(Brain cyclic nucleotide gated channel 1) (BCNG-1).  
0.082 264.456 0.0124 
ENSG00000135346 CGA Glycoprotein hormones alpha chain precursor (Anterior pituitary glycoprotein 
hormones common alpha subunit) (Follitropin alpha chain) (Follicle-stimulating 
hormone alpha chain) (FSH-alpha) (Lutropin alpha chain) (Luteinizing hormone 
alpha chain) (LSH-alph  
0.615 289.404 0.0129 
ENSG00000109205 NP_060325.2 APin protein  0.410 199.072 0.0143 
ENSG00000065328 MCM10 minichromosome maintenance protein 10 isoform 2  0.574 109.016 0.0147 
ENSG00000041802 LSG1  0.820 72.404 0.0149 
ENSG00000173950 NP_689744.2  0.205 273.981 0.0151 
ENSG00000168661 ZNF30 Zinc finger protein 30 (Zinc finger protein KOX28).  0.820 62.918 0.0152 
ENSG00000183862 CNGA2 Cyclic nucleotide-gated olfactory channel (Cyclic nucleotide-gated cation channel 
2) (CNG channel 2) (CNG-2) (CNG2) (Fragment).  
0.615 999.000 0.0153 
ENSG00000188636 LDOC1L  0.205 203.518 0.0154 
ENSG00000092200 RPGRIP1 X-linked retinitis pigmentosa GTPase regulator-interacting protein 1 (RPGR-
interacting protein 1).  
0.574 264.144 0.0162 
ENSG00000154358 OBSCN obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF  0.888 59.721 0.0168 
ENSG00000168229 PTGDR Prostaglandin D2 receptor (Prostanoid DP receptor) (PGD receptor).  1.640 999.000 0.0171 
ENSG00000198118 Q96R54_HUMAN Olfactory receptor (Fragment).  0.820 131.097 0.0171 
ENSG00000196074 SYCP2 Synaptonemal complex protein 2 (SCP-2 protein) (Synaptonemal complex lateral 
element protein) (hsSCP2).  
4.100 173.663 0.0173 
ENSG00000104853 CLPTM1 cleft lip and palate associated transmembrane protein 1  0.205 67.035 0.0181 
ENSG00000085982 USP40 Ubiquitin carboxyl-terminal hydrolase 40 (EC 3.1.2.15) (Ubiquitin thiolesterase 40) 
(Ubiquitin-specific-processing protease 40) (Deubiquitinating enzyme 40).  
0.351 161.113 0.0183 
ENSG00000160856 FCRL3 Fc receptor-like 3 precursor  0.246 246.953 0.0187 
ENSG00000181045 SLC26A11 solute carrier family 26, member 11  0.308 58.984 0.0191 
ENSG00000135540 NHSL1 NHSL1 protein (Fragment).  2.460 734.595 0.0193 
ENSG00000009790 TRAF3IP3 TRAF3-interacting JNK-activating modulator (TRAF3-interacting protein 3).  0.410 101.515 0.0195 
ENSG00000087206 RXINP_HUMAN Retinoid X receptor-interacting protein 110 (Receptor-associated protein 80) 
(Nuclear zinc finger protein RAP80).  
1.025 107.870 0.0196 
ENSG00000099399 MAGEB2 Melanoma-associated antigen B2 (MAGE-B2 antigen) (DSS-AHC critical interval 
MAGE superfamily 6) (DAM6) (MAGE XP-2).  
2.870 999.000 0.0201 
ENSG00000133773 CCDC59  0.410 184.628 0.0202 
ENSG00000197734 NP_777603.1  0.273 168.421 0.0206 












ENSG00000196735 HA25_HUMAN HLA class II histocompatibility antigen, DQ(5) alpha chain precursor (DC-1 alpha 
chain).  
0.478 39.209 0.0207 
ENSG00000079385 CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1 precursor (Biliary 
glycoprotein 1) (BGP-1) (CD66 antigen) (CD66a antigen).  
0.410 217.564 0.0209 
ENSG00000135968 GCC2 Ran-binding protein 2-like 4 (RanBP2L4).  0.769 54.241 0.0232 
ENSG00000169021 UQCRFS1 Ubiquinol-cytochrome c reductase iron-sulfur subunit, mitochondrial precursor (EC 
1.10.2.2) (Rieske iron-sulfur protein) (RISP).  
0.820 167.192 0.0233 
ENSG00000073067 CYP2W1 Cytochrome P450 2W1 (EC 1.14.14.-) (CYPIIW1).  0.410 57.026 0.0234 
ENSG00000148411 BTBD14A BTB (POZ) domain containing 14A  0.410 999.000 0.0236 
ENSG00000100312 ACR Acrosin precursor (EC 3.4.21.10) [Contains: Acrosin light chain; Acrosin heavy 
chain].  
0.273 109.920 0.0239 
ENSG00000175305 CCNE2 G1/S-specific cyclin-E2.  0.410 84.369 0.0243 
ENSG00000100450 GZMH Granzyme H precursor (EC 3.4.21.-) (Cytotoxic T-lymphocyte proteinase) 
(Cathepsin G-like 2) (CTSGL2) (CCP-X) (Cytotoxic serine protease C) (CSP-C).  
 999.000 0.0251 
ENSG00000198703 OR10R3P Seven transmembrane helix receptor.   999.000 0.0255 
ENSG00000160229 ZNF486 Zinc finger protein 486.  1.025 105.389 0.0260 
ENSG00000127838 PNKD myofibrillogenesis regulator 1 isoform 2  0.820 999.000 0.0265 
ENSG00000077935 SMC1L2 Structural maintenance of chromosome 1-like 2 protein (SMC1beta protein).   173.415 0.0270 
ENSG00000175885 ZNF611 zinc finger protein 611  0.410 181.404 0.0271 
ENSG00000112273 HDGFL1 hepatoma derived growth factor-like 1  1.435 51.016 0.0283 
ENSG00000179588 ZFPM1 Zinc finger protein ZFPM1 (Zinc finger protein multitype 1) (Friend of GATA 
protein 1) (Friend of GATA-1) (FOG-1).  
0.273 152.552 0.0288 
ENSG00000116254 CHD5 Chromodomain helicase-DNA-binding protein 5 (EC 3.6.1.-) (ATP- dependent 
helicase CHD5) (CHD-5).  
0.041 999.000 0.0292 
ENSG00000145850 TIMD4 T cell immunoglobulin and mucin domain-containing protein 4 precursor (TIMD-4) 
(T cell membrane protein 4) (TIM-4).  
 999.000 0.0294 
ENSG00000152782 PANK1 Pantothenate kinase 1 (EC 2.7.1.33) (Pantothenic acid kinase 1) (hPanK1) (hPanK).  0.205 138.333 0.0296 
ENSG00000115350 POLE4 DNA polymerase epsilon subunit 4 (EC 2.7.7.7) (DNA polymerase II subunit 4) 
(DNA polymerase epsilon subunit p12).  
0.273 36.136 0.0305 
ENSG00000125520 SLC2A4RG SLC2A4 regulator (GLUT4 enhancer factor) (GEF) (Huntington disease gene 
regulatory region-binding protein 1) (HDBP-1).  
0.820 111.824 0.0308 
ENSG00000101447 CT129_HUMAN 0.492 34.327 0.0309 
ENSG00000103855 CD276 CD276 antigen precursor (Costimulatory molecule) (B7 homolog 3) (B7- H3) (4Ig-
B7-H3).  
0.176 37.702 0.0309 
ENSG00000184278   0.547 175.020 0.0318 
ENSG00000162888 NP_001020763.1 1.025 999.000 0.0324 












ENSG00000186867 GPR103 Orexigenic neuropeptide QRFP receptor (G-protein coupled receptor 103) (SP9155) 
(AQ27).  
-2.870 999.000 0.0327 
ENSG00000085832 EPS15 Epidermal growth factor receptor substrate 15 (Protein Eps15) (AF-1p protein).  0.205 70.582 0.0339 
ENSG00000156574 NODAL Nodal homolog precursor.  0.308 40.588 0.0345 
ENSG00000091181 IL5RA Interleukin-5 receptor alpha chain precursor (IL-5R-alpha) (CD125 antigen) 
(CDw125).  
0.410 99.357 0.0354 
ENSG00000129103 SUMF2 Sulfatase-modifying factor 2 precursor (C-alpha-formyglycine- generating enzyme 
2).  
 999.000 0.0359 
ENSG00000197912 SPG7 Paraplegin (EC 3.4.24.-) (Spastic paraplegia protein 7).  1.025 71.642 0.0375 
ENSG00000129810 SGOL1 Shugoshin-like 1 (hSgo1) (Serologically defined breast cancer antigen NY-BR-85).   197.140 0.0376 
ENSG00000161914 ZNF653 zinc finger protein 653  0.103 999.000 0.0379 
ENSG00000139117 CPNE8 Copine-8 (Copine VIII).  0.082 999.000 0.0389 
ENSG00000196240 OR2T2 Olfactory receptor 2T2 (Olfactory receptor OR1-43).  0.273 42.879 0.0401 
ENSG00000152582 NP_653323.1 KPL2 protein isoform 2  4.920 7.647 0.0405 
ENSG00000169607 NP_689728.2  0.957 110.869 0.0406 
ENSG00000159433 STARD9 StAR-related lipid transfer protein 9 (StARD9) (START domain- containing protein 
9) (Fragment).  
0.559 525.103 0.0408 
ENSG00000187753 NP_001010907.1  999.000 0.0425 
ENSG00000145041 Q8TBD9_HUMAN VPRBP protein.  0.410 999.000 0.0428 
ENSG00000127366 TAS2R5 Taste receptor type 2 member 5 (T2R5).  2.050 999.000 0.0433 
ENSG00000165120 NP_660311.1   999.000 0.0456 
ENSG00000149418 ST14 Suppressor of tumorigenicity 14 (EC 3.4.21.-) (Matriptase) (Membrane- type serine 
protease 1) (MT-SP1) (Prostamin) (Serine protease TADG-15) (Tumor-associated 
differentially-expressed gene 15 protein).  
0.256 30.260 0.0463 
ENSG00000091592 NALP1 NACHT-, LRR- and PYD-containing protein 2 (Death effector filament- forming 
ced-4-like apoptosis protein) (Nucleotide-binding domain and caspase recruitment 
domain) (Caspase recruitment domain protein 7).  
2.870 999.000 0.0469 
ENSG00000180290 GNRHR2 Gonadotropin-releasing hormone II receptor (Type II GnRH receptor) (GnRH-II-R).   999.000 0.0477 
ENSG00000188869 TMC3 TMC3 protein.  0.461 999.000 0.0482 
1 Gene descriptions downloaded from Ensembl. Blanks indicate information not available or unknown.  
2 Nonsynonymous/synonymous substitution rate ratio, computed by 0.41n /s . Blank indicates no synonymous changes. 
3 Nonsynonymous/synonymous substitution rate ratio, computed by PAML for foreground site class 2b  









Genes showing significant signal of postive selection at FDR = 5% 
Lineage Ensembl Gene ID Gene Name Gene Description1 w2 w3 p-value   
Human ENSG00000165659 DACH1 Dachshund homolog 1 (Dach1).  0.205 999.000 0.0000 * 
  ENSG00000188153 COL4A5 Collagen alpha-5(IV) chain precursor.  0.205 999.000 0.0000 * 
Chimpanzee ENSG00000167522 ANKRD11 Ankyrin repeat domain-containing protein 11 (Ankyrin repeat-containing cofactor 
1).  
0.256 999.000 0.0000 * 
 ENSG00000126822 PLEKHG3 pleckstrin homology domain containing, family G, member 3  0.492 999.000 0.0000 * 
 ENSG00000152242 CR025_HUMAN 0.137 999.000 0.0000 * 
 ENSG00000117713 ARID1A AT-rich interactive domain-containing protein 1A (ARID domain- containing 
protein 1A) (SWI/SNF-related, matrix-associated, actin- dependent regulator of 
chromatin subfamily F member 1) (SWI-SNF complex protein p270) (B120) 
(SWI-like protein) (Osa homolog  
0.123 999.000 0.0000 * 
 ENSG00000185727   0.205 999.000 0.0000 * 
 ENSG00000165521 EML5 echinoderm microtubule associated protein like 5  0.252 999.000 0.0000 * 
 ENSG00000002746 HECW1 NEDD4-like ubiquitin-protein ligase 1  0.186 999.000 0.0000 * 
 ENSG00000198308 Q9NSI3_HUMAN 0.273 999.000 0.0000 * 
 ENSG00000116141 MARK1 Serine/threonine-protein kinase MARK1 (EC 2.7.1.37) (MAP/microtubule 
affinity-regulating kinase 1).  
0.410 999.000 0.0000 * 
 ENSG00000091986 NP_955806.1 steroid-sensitive protein 1  0.351 999.000 0.0000 * 
 ENSG00000147036 LANCL3 LanC lantibiotic synthetase component C-like 3  0.205 999.000 0.0000 * 
 ENSG00000112276 BVES Blood vessel epicardial substance (hBVES) (Popeye domain-containing protein 1) 
(Popeye protein 1).  
0.273 999.000 0.0000 * 
 ENSG00000106415 GLCCI1 glucocorticoid induced transcript 1  0.205 999.000 0.0000 * 
 ENSG00000130227 XPO7 Exportin-7 (Ran-binding protein 16).  0.205 999.000 0.0000 * 
 ENSG00000096401 CDC5L Cell division cycle 5-like protein (Cdc5-like protein) (Pombe cdc5- related 
protein).  
0.164 999.000 0.0000 * 
 ENSG00000126010 GRPR Gastrin-releasing peptide receptor (GRP-R) (GRP-preferring bombesin receptor).  0.273 999.000 0.0000 * 
 ENSG00000100345 MYH9 Myosin-9 (Myosin heavy chain, nonmuscle IIa) (Nonmuscle myosin heavy chain 
IIa) (NMMHC II-a) (NMMHC-IIA) (Cellular myosin heavy chain, type A) 
(Nonmuscle myosin heavy chain-A) (NMMHC-A).  
0.112 211.772 0.0000 * 
 ENSG00000129116 PALLD palladin  0.059 999.000 0.0000 * 
 ENSG00000197996 PADI6 Peptidylarginine deiminase type VI (EC 3.5.3.15) (Peptidylarginine deiminase 
type 6).  
0.246 915.618 0.0000 * 
 ENSG00000198700 IPO9 Importin-9 (Imp9) (Ran-binding protein 9) (RanbP9).  0.824 999.000 0.0000 * 
 ENSG00000123607 TTC21B tetratricopeptide repeat domain 21B  0.205 999.000 0.0000 * 
 ENSG00000178662 TAIP2_HUMAN TGF-beta-induced apoptosis protein 2 (TAIP-2).  0.082 999.000 0.0000  







Lineage Ensembl Gene ID Gene Name Gene Description1 w2 w3 p-value   
 ENSG00000059588 TARBP1 TAR RNA binding protein 1  0.256 999.000 0.0000  
 ENSG00000144130 NT5DC4  0.342 984.278 0.0000  
 ENSG00000180530 NRIP1 Nuclear receptor-interacting protein 1 (Nuclear factor RIP140) (Receptor-
interacting protein 140).  
0.273 999.000 0.0000  
 ENSG00000102385 DRP2 Dystrophin-related protein 2.  0.273 999.000 0.0000  
 ENSG00000125772 K1434_HUMAN 0.137 999.000 0.0000  
 ENSG00000133619 NP_115923.1  0.293 379.927 0.0000  
 ENSG00000136014 USP44 Ubiquitin carboxyl-terminal hydrolase 44 (EC 3.1.2.15) (Ubiquitin thiolesterase 
44) (Ubiquitin-specific-processing protease 44) (Deubiquitinating enzyme 44).  
0.410 999.000 0.0000  
 ENSG00000198171 CT116_HUMAN Protein C20orf116 precursor.  0.205 999.000 0.0000  
 ENSG00000198265 HELZ Probable helicase with zinc-finger domain (EC 3.6.1.-).  0.410 999.000 0.0000  
 ENSG00000166012 JOSD3  0.273 999.000 0.0000  
 ENSG00000152422 XRCC4 DNA-repair protein XRCC4 (X-ray repair cross-complementing protein 4).  0.410 999.000 0.0000  
 ENSG00000185834   0.820 999.000 0.0000  
 ENSG00000169957 NP_078947.2  0.273 999.000 0.0000  
 ENSG00000105216 LSM14A Protein FAM61A (Putative alpha synuclein-binding protein) (AlphaSNBP).  0.308 999.000 0.0000  
 ENSG00000135605 TEC Tyrosine-protein kinase Tec (EC 2.7.1.112).  0.342 999.000 0.0000  
 ENSG00000124496 TRERF1 Transcriptional-regulating factor 1 (Transcriptional-regulating protein 132) (Zinc 
finger transcription factor TReP-132) (Zinc finger protein rapa).  
0.308 999.000 0.0000  
 ENSG00000100368 CSF2RB Cytokine receptor common beta chain precursor (GM-CSF/IL-3/IL-5 receptor 
common beta-chain) (CD131 antigen) (CDw131).  
0.492 999.000 0.0000  
 ENSG00000113269 RNF130 Goliath homolog precursor (RING finger protein 130).  0.103 999.000 0.0000  
 ENSG00000013503 POLR3B DNA-directed RNA polymerase III subunit 127.6 kDa polypeptide (EC 2.7.7.6) 
(RNA polymerase III subunit 2) (RPC2).  
0.117 999.000 0.0000  
 ENSG00000162341 TPCN2 two pore segment channel 2  0.410 999.000 0.0000  
 ENSG00000189257   0.308 999.000 0.0000  
 ENSG00000166540 NP_060227.1 zinc finger protein 407  0.205 128.727 0.0001  
 ENSG00000136383 ALPK3 alpha-kinase 3  0.513 325.969 0.0001  
 ENSG00000182646 TMEM29  0.410 999.000 0.0001  
 ENSG00000116750 UCHL5 Ubiquitin carboxyl-terminal hydrolase isozyme L5 (EC 3.4.19.12) (UCH- L5) 
(Ubiquitin thiolesterase L5) (Ubiquitin C-terminal hydrolase UCH37).  
0.410 999.000 0.0001  
 ENSG00000188683   0.410 941.509 0.0001  
 ENSG00000160299 PCNT Pericentrin (Pericentrin B) (Kendrin).  0.308 999.000 0.0001  
 ENSG00000126337 KRTHA6 Keratin, type I cuticular Ha6 (Hair keratin, type I Ha6).  0.308 516.751 0.0001  
 ENSG00000176819   0.820 999.000 0.0001  
 ENSG00000152455 SUV39H2 Histone-lysine N-methyltransferase, H3 lysine-9 specific 2 (EC 2.1.1.43) (Histone 
H3-K9 methyltransferase 2) (H3-K9-HMTase 2) (Suppressor of variegation 3-9 







Lineage Ensembl Gene ID Gene Name Gene Description1 w2 w3 p-value   
homolog 2) (Su(var)3-9 homolog 2).  
 ENSG00000053524 MCF2L2 Rho family guanine-nucleotide exchange factor  0.273 999.000 0.0001  
 ENSG00000095637 SORBS1 Sorbin and SH3 domain-containing protein 1 (Ponsin) (c-Cbl-associated protein) 
(CAP) (SH3 domain protein 5) (SH3P12).  
0.234 999.000 0.0001  
 ENSG00000182405 PGBD4 piggyBac transposable element derived 4  0.273 999.000 0.0002  
 ENSG00000077063 CTTNBP2 cortactin binding protein 2  0.308 999.000 0.0002  
 ENSG00000139625 MAP3K12 Mitogen-activated protein kinase kinase kinase 12 (EC 2.7.1.37) (Mixed lineage 
kinase) (Leucine-zipper protein kinase) (ZPK) (Dual leucine zipper bearing 
kinase) (DLK) (MAPK-upstream kinase) (MUK).  
0.410 999.000 0.0002  
  ENSG00000189180 ZNF11A Zinc finger protein 33A (Zinc finger protein KOX31) (HA0946).  0.574 999.000 0.0002   
1 Gene descriptions downloaded from Ensembl. Blanks indicate information not available or unknown.    
2 Nonsynonymous/synonymous substitution rate ratio, computed by 0.41n /s .     
3 Nonsynonymous/synonymous substitution rate ratio, computed by PAML for foreground site class 2b   









 Genes showing significant signal of postive selection and associated with human disease 









Both ENSG00000141458 NPC1 Niemann-Pick C1 protein precursor.  257220 Niemann-Pick disease, type C 
(3) 
257220 Niemann-Pick disease, type D, 
257250 (2) 
Chimp ENSG00000001626 CFTR Cystic fibrosis transmembrane conductance regulator 
(CFTR) (cAMP- dependent chloride channel) (ATP-
binding cassette transporter sub- family C member 7).  
602421 Congenital bilateral absence of 
vas deferens, 277180 (3) 
602421 Cystic fibrosis, 219700 (3) 
602421 Sweat chloride elevation without 
CF (3) 
ENSG00000100312 ACR Acrosin precursor (EC 3.4.21.10) [Contains: Acrosin light 
chain; Acrosin heavy chain].  
102480 Male infertility due to acrosin 
deficiency (2) (?) 
ENSG00000100368 CSF2RB Cytokine receptor common beta chain precursor (GM-
CSF/IL-3/IL-5 receptor common beta-chain) (CD131 
antigen) (CDw131).  
138981 Pulmonary alveolar proteinosis, 
265120 (3) 
ENSG00000101076 HNF4A Hepatocyte nuclear factor 4-alpha (HNF-4-alpha) 
(Transcription factor HNF-4) (Transcription factor 14).  
600281 MODY, type 1, 125850 (3) 
600281 Non-insulin-dependent diabetes 
mellitus, 125853 (3) 
ENSG00000103449 SALL1 Sal-like protein 1 (Zinc finger protein SALL1) (Spalt-like 
transcription factor 1) (HSal1).  
602218 Townes-Brocks syndrome, 
107480 (3) 
ENSG00000113905 HRG Histidine-rich glycoprotein precursor (Histidine-proline-
rich glycoprotein) (HPRG).  
142640 Thrombophilia due to elevated 
HRG (1) (?) 
ENSG00000135346 CGA Glycoprotein hormones alpha chain precursor (Anterior 
pituitary glycoprotein hormones common alpha subunit) 
(Follitropin alpha chain) (Follicle-stimulating hormone 
alpha chain) (FSH-alpha) (Lutropin alpha chain) 
(Luteinizing hormone alpha chain) (LSH-alph  
307150 Hypertrichosis, congenital 
generalized (2) 
ENSG00000135605 TEC Tyrosine-protein kinase Tec (EC 2.7.1.112).  148500 Tylosis with esophageal cancer 
(2) 
ENSG00000173230 GOLGB1 Golgin subfamily B member 1 (Giantin) (Macrogolgin) 
(372 kDa Golgi complex-associated protein) (GCP372).  
303800 Colorblindness, deutan (3) 

















Human ENSG00000102805 CLN5 Ceroid-lipofuscinosis neuronal protein 5 (Protein CLN5).  256731 Ceroid-lipofuscinosis, neuronal-
5, variant late infantile (3) 
ENSG00000122971 ACADS Acyl-CoA dehydrogenase, short-chain specific, 
mitochondrial precursor (EC 1.3.99.2) (SCAD) (Butyryl-
CoA dehydrogenase).  
201470 Acyl-CoA dehydrogenase, 
short-chain, deficiency of (3) 
ENSG00000133805 AMPD3 AMP deaminase 3 (EC 3.5.4.6) (AMP deaminase isoform 
E) (Erythrocyte AMP deaminase).  
102772 [AMP deaminase deficiency, 
erythrocytic] (3) 
ENSG00000138029 HADHB Trifunctional enzyme beta subunit, mitochondrial precursor 
(TP-beta) [Includes: 3-ketoacyl-CoA thiolase (EC 2.3.1.16) 
(Acetyl-CoA acyltransferase) (Beta-ketothiolase)].  
143450 Trifunctional protein deficiency, 
type II (3) 
ENSG00000141837 CACNA1A Voltage-dependent P/Q-type calcium channel alpha-1A 
subunit (Voltage- gated calcium channel alpha subunit 
Cav2.1) (Calcium channel, L type, alpha-1 polypeptide 
isoform 4) (Brain calcium channel I) (BI).  
601011 Cerebellar ataxia, pure (3) 
601011 Episodic ataxia, type 2, 108500 
(3) 
601011 Hemiplegic migraine, familial, 
141500 (3) 
601011 Spinocerebellar ataxia-6, 
183086 (3) 
ENSG00000147889 CDKN2A Cyclin-dependent kinase inhibitor 2A, isoform 4 (p14ARF) 
(p19ARF).  
155600 Malignant melanoma, cutaneous 
(2) 
600160 Melanoma, 155601 (3) 
ENSG00000163069 SGCB Beta-sarcoglycan (Beta-SG) (43 kDa dystrophin-associated 
glycoprotein) (43DAG) (A3b).  
600900 Muscular dystrophy, limb-
girdle, type 2E (3) 
ENSG00000165125 TRPV6 Transient receptor potential cation channel subfamily V 
member 6 (TrpV6) (Epithelial calcium channel 2) (ECaC2) 
(Calcium transport protein 1) (CaT1) (CaT-like) (CaT-L).  
600184 Carnitine acetyltransferase 
deficiency (1) (?) 
ENSG00000165409 TSHR Thyrotropin receptor precursor (TSH-R) (Thyroid-
stimulating hormone receptor).  
275200 Graves disease, 275000 (1) 
275200 Hyperthroidism, congenital (3) 
275200 Hypothyroidism, nongoitrous, 
due to TSH resistance (3) 
275200 Thyroid adenoma, 
hyperfunctioning (3) 
ENSG00000169738 DCXR L-xylulose reductase (EC 1.1.1.10) (XR) (Dicarbonyl/L-
xylulose reductase) (Kidney dicarbonyl reductase) (kiDCR) 
(Carbonyl reductase II) (Sperm surface protein P34H).  

















ENSG00000180509 KCNE1 Potassium voltage-gated channel subfamily E member 1 
(IKs producing slow voltage-gated potassium channel beta 
subunit Mink) (Minimal potassium channel) (Delayed 
rectifier potassium channel subunit IsK).  
176261 Jervell and Lange-Nielsen 
syndrome, 220400 (3) 
ENSG00000182372 CLN8 Protein CLN8.  600143 Epilepsy, progressive, with 
mental retardation (2) 
ENSG00000186395 KRT10 Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) 
(Keratin-10) (K10).  
148080 Epidermolytic hyperkeratosis, 
113800 (3) 
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